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The straw mushroom Volvanella volvacea is one of the common edible mushrooms 
in Hong Kong and is widely cultivated in South-East Asian countries. Many 
mushrooms are known to have medicinal values, such as hypotensive or 
hypolipidemic effects, but in the straw mushroom, the medicinal effects are unknown. 
The present study was directed to provide some information on these putative 
functions. Aqueous straw mushroom extract (SME) was prepared and given through 
intravenous injections, or orally to rats. The hypotensive effect and hypolipidemic 
effect were studied by measuring changes in blood pressure, serum triglyceride and 
cholesterol levels. The blood pressure changes produced by SME were also studied 
in the presence of various drugs. The effects of SME on isolated preparations of tail 
artery strips and right atria were studied as well. 
SME produced a hypotensive effect in rats upon intravenous injections with ED50 of 
25 mg dry weight per kg body weight. This hypotensive effect of SME might act via 
the autonomic system, the a-adrenergic system, and/or histaminergic stimulation. 
V 
Besides, it increased urinary excretion. The interaction of all these components 
resulted in an overall decrease in blood pressure. During in vitro study, SME showed 
positive inotropic and chronotropic effects on the isolated right atrium and induced 
contraction of the isolated tail artery. SME must contain vasoactive substance(s), such 
as adrenergic-like substances. The active substances were found in a dialyzed sample 
with molecular mass between 8000 and 12000 dalton, which would provide a good 
source of cardiovascular active substances if further purification steps were 
conducted. 
Acute oral feeding of SME did not decrease the blood pressure significantly. SME 
did not show any hypolipidemic effect even when normotensive rats were given 400 
mg/kg daily for 8 weeks. 
It was concluded that SME showed a hypotensive effect when given i.v. but not via 
oral route. It did not produce a hypolipidemic effect. 
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INTRODUCTION 
There are over a hundred species, subspecies and varieties of Volvariella (Chang and 
Miles, 1986), many of them being cultivated for food consumption. Most of the 
cultivated forms of Volvariella found in Southeast Asia are members of the species 
Volvariella volvacea (Bull.ex Fr.) Sing, and，straw mushroom，is the common name. 
It is one of the common edible mushrooms in Hong Kong. The "button" and "egg" 
stages (Appendix VI) are commonly seen because they are usually sold in the 
markets. They are ovoid in shape and the whole structure is wrapped by a coat which 
is called the universal veil. In 1971, cotton wastes were first introduced as a compost 
material by Chang, and later completely replaced the traditional paddy straw used for 
cultivation of the mushroom in Hong Kong. This was a turning point in the straw 
mushroom history, because the cotton waste compost gives a higher and more stable 
yield (24-45%), earlier fructification and earlier harvesting than that obtained using 
straw as the substratum under the same conditions (Chang and Miles, 1986). The 
mushroom's short life cycle, easily cultivation, high productivity, ability to recycle 
waste materials, high nutritive values and wide habitat explained the rapid increase 
of production in many different South-east Asian countries (Chang and Miles, 1986). 
1 
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It has now been demonstrated that straw mushrooms have genuine nutritional value 
and serve as a source of dietary protein, essential amino acids, vitamins and minerals 
(Jong and Birmingham, 1990). Furthermore, straw mushrooms have been served in 
table dishes because of their good palatability which includes acceptable color, good 
texture and special flavor (Huang, 1987). 
The practice of using fungi as medicines has been found in the traditions of many 
cultures, past and present. Breene (1990) reviewed that a number of species have 
medicinal and therapeutic value in the prevention and treatment of cancer, viral 
disease, hypercholesterolemia, blood platelet aggregation and hypertension. Although 
the medicinal benefits of straw mushrooms remain largely unknown and therefore 
unexploited, its potential medicinal values cannot be ignored. The straw mushroom 
would suppress 68% of sarcoma-180 tumor growth in mice (Breene, 1990). The 
inhibition rate was greater when mice were fed with mushroom over a longer period 
of time. Breene (1990) suggested that the ingredients present in the mushroom might 
activate the cellular immune system. The anti-tumor effect might also be due to the 
presence of the cardiotonic proteins (volvatoxin), which might be able to inhibit the 
respiration of Ehrlich ascites tumor cells. However, the toxicity and protein nature 
of these cardiotoxic substances seem to limit their potential usefulness at this stage. 
Therefore, more research work is required to maximize the benefits of straw 
mushrooms and to eliminate the harmful effects caused. 
Hypertension is the most widespread cardiovascular disease. It causes secondary 
diseases if it is not suppressed immediately, such as hypertrophy of the heart, angina 
pectoris, coronary occlusion, arteriosclerosis, renal disease and cerebral hemorrhage. 
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Some edible mushrooms have been reported to be hypotensive (Huang, 1987), such 
as TremellaJuciformis, Flammulina velutipes, Hericiim crinaceus, Agaricus bisporus, 
Pleurotus ostreatus and Lentinus edodes. 
Huang (1987) suggested that Volvariella volvacea was hypotensive because it could 
lower the cholesterol level inside the blood stream. Coronary disease, hypertension, 
atherosclerosis, diabetes and gallstones are highly related to cholesterol levels. Since 
some edible mushrooms have been reported to be hypolipidemic, one of the areas in 
my research was to investigate if this applied to V. volvacea. 
The major theme of the research was to study the hypotensive effect of straw 
mushrooms, and its mechanisms. Only aqueous boiled straw mushroom extracts were 
used because as little as 10 mg/kg unboiled straw mushroom extract (SME) caused 
the death of rats probably due to the presence of volvatoxin. Lin (1973) reported that 
volvatoxin caused ventricular systolic arrest in tested animals. The toxicity of 
volvatoxin was eliminated by heating at 100°C for 20 minutes. 
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LITERATURE REVIEW 
A. Some Aspects of Cardiovascular Physiology and Pharmacology 
I. Fundamental Principles Governing Regulation of Arterial Pressure 
Introduction 
The most important physical characteristics of the circulation are volume, 
pressure, and flow. Volume and volume-pressure relations comprise the static of 
the system and define the basic qualities that distinguish important functional 
properties of arteries and veins. Pressure and flow relate to the moving stream 
of blood and characterize the dynamics of the circulation. Total blood volume in 
the healthy human adult is 75 ml/kg. Individual variations depend mainly on age, 
climate, and degree of physical activity. 
It has been estimated that in a normal 70 kg adult with a total blood volume of 
about 5000 ml and thoracic blood volume of about 1250 ml, about 350 ml would 
be contained in the vena cavae and right heart and thus serve in a sense as the 
right heart reserve. About 900 ml are contained in the pulmonary artery, lungs, 
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pulmonary veins, and left ventricle. Thoracic blood volume thus constitutes an 
immediate source of filling pressure and volume for the two ventricles. This 
reserve is important, since ventricular filling is a critical determinant of stroke 
volume and cardiac output (Smith and Kampine, 1990). The cardiac output for 
the young adult female is about 5 liters per minute; that for the young adult male 
of the same age and size is 5.6 liters per minute. In strenuous exercise, the 
cardiac output of a well-trained athlete may reach levels as high as 35 liters per 
minute (Strand, 1979). 
Blood pressure is generated by forceful contraction of the heart so as to pump 
blood in the circulation to every part of the body to provide nutrients. Blood 
pressure is defined as the force that the blood exerts against the walls of the 
blood vessels (Guyton, 1984). In the non-medical sciences, pressures are usually 
measured in International System (SI) units, the SI unit for pressure is the Nm'^  
(the pascal, Pa). In physiology and medicine, however, it is more customary to 
use the secondary unit mmHg. 1 mmHg is equal to 133.3 Pa which is equal to 
0.013 k Pa, therefore a blood pressure of 120/80 mmHg becomes approximately 
16.0/10.6 k Pa (Kelman, 1979). In keeping with normal clinical practice blood 
pressure in this thesis is given in mmHg. 
Traditionally, blood pressure is measured by mercury manometers. 
Unfortunately, mercury in the mercury manometer has so much inertia that it 
cannot rise and fall rapidly. Thus, it was later replaced by other pressure 
recorders (Guyton, 1984). There are several types of pressure recorders, their 
basic mechanical operations are similar. The pressure recorders are composed of 
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two instruments, one is a transducer and the other is a electronic recorder. A 
syringe needle is connected to each transducer; this needle is inserted directly 
into the vessel, the pressure of which is to be measured. The pressure being 
measured is transmitted into a chamber blinded on one side by a thin membrane, 
which forms one plate of a variable capacitor. As the pressure rises, the 
membrane moves closer to the other plate and changes the electrical capacitance, 
which is detected and recorded by an electronic recorder as mentioned before 
(Guyton, 1984). 
The arterial pressure is generated by the systolic ejection of blood into the 
arterial tree. The mean arterial pressure (MAP) is the average pressure 
throughout each cycle of the heart. It can actually be determined by integrating 
the area of the pressure curve (Li, 1989). For simplicity, it is approximately 
equal to the summation of diastolic pressure and one-third of the pulse pressure 
which is the difference of systolic and diastolic pressures (Kelman, 1979). 
According to Strand (1978), the average pressure in a cardiac cycle is usually 
100 mmHg. 
Strand (1978) defined systolic pressure as "the pressure generated by the 
contraction of the heart, and modified by the elasticity of the arteries. It averages 
120 mmHg in the large arteries of young adults." Morris (1975) gave an 
analogous explanation of systolic pressure. He stated that systolic pressure 
records the force exerted in the arteries with each heart beat or contraction to 
propel the blood out of the left ventricle of the heart into the aorta, the large 
artery, while the diastolic pressure records that in the large arteries (luring 
6 
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relaxation of the heart and indicates the degree of recoil of the arteries. The 
average diastolic pressure is 80 mmHg (Strand, 1978). It should be noted that 
normal systolic and diastolic pressure vary in different age groups (Appendix I). 
Regulation of arterial pressure 
a. The reasons for regulation of arterial pressure 
Before discussing how the body regulates arterial pressure, one may ask why 
arterial pressure has to be regulated. Guyton (1980) proposes four reasons. 
Firstly, the overall goal of cardiovascular regulation is to provide proper 
blood flow through each organ, arterial pressure regulation is one of the bases 
for achieving that. Control of arterial pressure provides a steady pressure 
head for microregulation of other parts of the body. Secondly, a proper 
control of arterial pressure may prevent the blood flow needs of one part of 
the body from interfering with blood flow to other parts of the body. For 
instance, it is assumed that during physical exercises there is no arterial 
pressure control. The tremendous vasodilation that occurs in the muscles 
during physical exercises would cause a very serious drop in arterial pressure 
and thereby to the brain. 
Thirdly, an arterial pressure control system allows the body to adjust the 
arterial pressure to various bodily needs. Thus, during sleep, the pressure 
decreases and thereby conserves the energy of the heart. Finally, long-term 
control of pressure day in and day out provides a pressure that is not 
pathologically damaging to the circulation itself. Therefore, in essence, the 
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philosophy of arterial blood pressure regulation is to provide a constant 
pressure head that is high enough so that any tissue can call for a greatly 
increased blood flow upon demand, and yet a pressure that is reasonably 
constant so that the blood flow controlling apparatus can always be assured 
of a source of blood pressure upon demand but, also, a pressure that is not 
high that the energy load on the heart is deleterious to long-term survival to 
the heart and that it is damaging to the blood vessels. 
b. Mechanisms of regulation of arterial pressure 
Blood pressure basically is altered by two important factors, they are cardiac 
output (stroke volume x heart rate) and peripheral vascular resistance. 
Volume of venous blood returning to the heart, the size of the heart, 
contractile strength of the heart, and also rate of the heart affect the stroke 
volume. The peripheral resistance is inversely proportional to the diameter of 
the blood vessels and directly proportional to the viscosity of the blood 
(Strand, 1978). One may expect that the arterial pressure changes if any one 
of the above factors changes. To understand how the arterial pressure is 
controlled inside the body, an understanding of a hierarchy of pressure 
control systems recommended by Guyton et a/. (1981) may be helpful. For 
instance, a person suffers from a severe hemorrhage, that is, an extensive 
bleeding. The arterial pressure regulating device reacts almost instantaneously 
to any aberration in pressure. This will be followed by various control 
systems being activated in sequence to restore blood pressure to normal. 
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(1). Responses within seconds 
Three different nervous control systems begin to function. The first one 
is the baroreceptors located in the neck region and near the heart region. 
They detect the changes in blood pressure and send appropriate reflex 
signals back to the heart and blood vessels to return the pressure toward 
normal. The signals are transmitted to the vasomotor center of the 
hindbrain and hence back to the circulation to alter the strength of the 
heart contraction and the degree of constriction of the peripheral blood 
vessels (Guyton, 1980). The second control system is the 
chemoreceptors which detect a change in the delivery of oxygen to or 
removal of carbon dioxide from the tissues. They also produce an 
appropriate neural feedback response to correct the pressure 
abnormality. Chemoreceptors are located in the two carotid bodies and 
the group of aortic bodies (Strand, 1978). Shepherd (1983) reported that 
carotid chemoreceptors are stimulated by hemorrhagic hypotension. The 
third one is the vasomotor center in the medulla: appropriate feedback 
signals are invoked also to return the pressure to normal. 
The responses of short-term control of the arterial pressure are 
summarized in Appendix II which shows a simplified schema showing 
primary pathways for short-term regulation of arterial blood pressure 
(Smith and Kampine, 1990). It must be noted that no single one of the 
nervous controls of arterial pressure can return the arterial pressure all 
the way back to its normal value following an abnormal rise or fall. 
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Therefore, in the main, the nervous controls serve to buffer the arterial 
pressure rather than to provide long-term control (Guyton, 1980). 
(2). Responses within minutes 
Other control systems react slowly to affect pressure in the following 
minutes. Firstly, the blood vessels slowly stretch if the pressure is too 
high or slowly contract if the pressure is too low. The stress relaxation 
system may involve sympathetic nervous system. If the blood pressure 
is too high, signals from the baroreceptors in the neck and heart regions 
will be sent to inhibit the response of sympathetic vasoconstrictor 
nervous system which will regulate peripheral resistance of arterioles 
mainly in splanchnic area and in the skin (Schlittler, 1967). The 
processes of regulation of sympathetic vasoconstrictor nervous system 
involve some vasoactive agents. Circulating vasoconstrictors are 
catecholamine, angiotensin, vasopressin and dopamine, while the 
circulating vasodilators are histamine, prostaglandin, and kinin (Brady, 
1981; Strand, 1978). 
Secondly, the renin-angiotensin system, which becomes activated when 
the pressure falls too low; renin converts angiotensin I to angiotensin 
II to be formed in the circulating blood, and angiotensin II then 
constricts the peripheral arterioles to raise the pressure back toward 
normal. Renin is produced by the juxtaglomerular apparatus which is 
composed of granular, modified smooth muscle cells, in the afferent 
glomerular arterioles. The cells are sensitive to the renal arteriolar blood 
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pressure. A decrease of blood pressure in the afferent glomerular 
arterioles causes secretion of the enzyme renin into the renal venous 
blood. Once the renin is released into the blood stream, it catalyses the 
breakdown of an ofj-globulin, angiotensinogen, forming the decapeptide 
angiotensin I. This is then converted into the octapeptide angiotensin II, 
which causes widespread vasoconstriction and a subsequent rise of the 
arterial blood pressure (Kelman, 1979). A diagram given by Strand 
(1978) summarizes the function of the renin-angiotensin system 
(Appendix III). 
Thirdly, the capillary fluid shift mechanism; when the pressure falls too 
low, fluid is absorbed into the capillaries and if the pressure rises too 
high, fluid is lost from the circulation. 
(3). Long term regulation of arterial pressure 
Smith and Kampine (1990) summarized renal-body fluid mechanism for 
long-term regulation of arterial blood pressure (Appendix IV). Here an 
increase in arterial pressure causes an increase in fluid output through 
the kidneys, leading to a reduction in extracellular fluid volume, then a 
decrease in blood volume with a decrease in the venous return. 
Consequently a decrease in cardiac output will further reduce the arterial 
pressure. When the pressure falls excessively low, the aldosterone by 
resorption of sodium in the tubule in turn causes the kidneys to retain 
salt and water, thereby helping to return the pressure back to normal. 
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Another mechanism is the renal-blood-volume-pressure control system. 
An increase in renal arterial pressure above normal markedly increases 
the urinary output of sodium and water, whereas a decrease in arterial 
pressure reduces urinary output. In turn, changes in urinary output affect 
body fluid volumes and cardiac output, and hence arterial pressure. 
n . Hypertension 
Definition of hypertension 
As with many conditions, sometimes it is difficult to distinguish normotension 
from hypertension. Arterial blood pressure increases with age, even in normal 
people; and moreover there is, in any homogenous age group, a continuous 
gradation between the blood pressure of individuals who are clearly normal and 
of those who are unequivocally hypertensive (Kelman, 1979). For the sake of 
simplicity and unity, many physicians regard a patient as hypertensive if as the 
patient is suffered from chronic elevation of diastolic pressure above 90 mmHg 
and/or systolic pressure above 140 mmHg. Kaplan (1981) defined mild 
hypertension as diastolic blood pressure between 90 and 104 mmHg. Smith and 
Kampine (1990) suggested that a patient is classified as hypertensive when 
repeated resting levels of the systolic and diastolic pressure are greater or equal 
to 140 and 90 mmHg in adults of 18 to 49 years old and greater or equal to 160 
and 95 mmHg in adults of over 50 years old. 
Hypertension is found more common among males than females, and severe 
hypertension is four times more common in black men than in white. Besides, 
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the tolerance of hypertension is different from individuals (Schlittler, 1967; Smith 
and Kampine, 1990). 
Different types of hypertension are classified according to the causes or the 
symptoms of the diseases. For example, systolic hypertension is the condition in 
which the systolic rise is more prominent than diastolic pressure. Hypertension 
with known causes is termed as secondary hypertension (Smith and Kampine, 
1990). On the other hand, 95% of cases involve no obvious causative factor, and 
are grouped as essential hypertension (Rang and Dale, 1987). 
Causes of hypertension 
a. Theories of hypertension 
These include vascular adaptive changes, psychosocial stimulus theory, 
myogenic theory and autoregulation theory (Iriuchijima, 1982). The first 
theory is vascular adaptive changes. It has been noted that blood pressure is 
easily elevated transiently due to many daily activities, such as driving a car, 
speech, discussion, and taking care of children. Some respond to it by 
hypertrophy of smooth muscle of the resistance vessels and then become 
hypertensive. The thickened muscle layer would encroach more upon the 
lumen when the arterioles constrict. This would result in a greater resistance 
to blood flow. 
The second theory, relating hypertension with social and hormonal factors, 
is called psychosocial stimulus theory. It is argued that stress in daily social 
life is one of the important factors for hypertension. It has been noted that 
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blood pressure became elevated in male and female mice when they were 
suddenly exposed to a social life with other mice after having been kept in 
isolation in pint fruit jars for the first 4 months after weaning. The social life 
in these experiments consisted in cohabitation of 16 male mice and 16 female 
mice in an intercommunicating seven-box system. Blood pressure remained 
elevated for several months upon returning the mice to isolation. 
The myogenic theory is associated with a true vascular hypertrophy. Certain 
forms of hypertension are due to a primary disease of vascular smooth 
muscle, rather than to excessive vasoconstrictory stimuli. 
The autoregulation theory states that the cause of hypertension is present in 
the kidney, not as an organ in the renin-angiotensin context but as the organ 
for urine excretion. When the excretory function of water and salt in the 
kidney is lowered, water is accumulated in the body then the body tissue fluid 
is increased. The increase in tissue fluid induces a shift of water from tissue 
to blood resulting in an increase in volume which induces an increase in 
venous return and cardiac output, and finally elevates blood pressure. 
b. Causes of hypertension 
In the majority of cases, systemic hypertension is of unknown etiology. About 
5% of hypertension is due to some abnormalities of the body. Hypertension 
which occurs with pheochromocytoma (phaeochromocytoma) has been well 
understood (Kelman, 1979; Rang and Dale, 1987; Schlittler, 1967). Tumors 
arise from chromaffin tissue or in the adrenal medulla. They secrete 
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catecholamine (adrenaline and noradrenaline) and cause hypertension, often 
in the form of paroxysms in which the blood pressure rises precipitously. 
There are accompanying signs and symptoms of adrenal oversecretion: pallor 
of the extremities, tremor, anxiety, tachycardia, and sweating. 
Over-secretion of aldosterone by a tumor of the adrenal cortex produces mild 
or moderate hypertension (Rang and Dale, 1987). The hypertension is 
probably related to sodium retention, as a result of the action of aldosterone 
on the distal part of the nephron. Cushing's syndrome is another etiological 
cause of hypertension (Kelman, 1979). The disease is due to oversecretion of 
Cortisol from the adrenal cortex, either as a result of hypertrophy or tumor 
formation, or of oversecretion of adrenocorticotrophic hormone (ACTH) from 
the anterior pituitary. These secretions will disturb the balance of sodium ions 
inside the body, which will eventually lead to disturbance of regulation of 
blood pressure. 
The main secondary cause of hypertension is renal disease (Liard, 1979; 
Smith and Kampine, 1990). Sometimes, damaged kidneys secrete large 
amounts of renin, which in turn leads to formation of angiotensin which is a 
vasoconstrictor and increases the total peripheral resistance. This sequence 
occurs especially in the condition called malignant hypertension (Guyton, 
1984). The vasoconstriction obviously can act in concert with the excess 
blood volume effect that occurs in kidney disease to cause very severe 
hypertension. 
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Renal diseases include renovascular hypertension and renal parenchymal 
abnormality. Renovascular hypertension is the result of stenosis of one or 
both renal arteries, usually caused by atherosclerosis or fibromuscular 
hyperplasia. Renovascular hypertension leads to renin and angiotensin II 
oversecretions and improper retention of sodium and water (Kelman, 1979). 
Angiotensin II raises arterial pressure because it is a potent vasoconstrictor 
(Smith and Kampine, 1990). 
In old people, the elasticity of the arteries has lost, the heart must pump 
forcibly, with a resulting rise in the systolic pressure (Morris, 1975). 
Furthermore, narrowing of arterioles is another reason of hypertension, which 
is usually due to accumulation of cholesterol in blood vessels (Morris, 1975). 
m. Antihypertensive Substances 
Introduction 
A good theory of hypothesis of hypertension would be expected to explain not 
only how the hypertensive state is induced and maintained but also how it is 
beneficially affected by suitable antihypertensive drugs. As an antihypertensive 
agent, it should induce a decrease in blood pressure that is of slow onset, not too 
pronounced, and similar in supine and standing positions. Antihypertensive agents 
have a duration of action of 12 to 24 hours. They should not produce 
tachycardia. They do not cause tolerance or produce adverse reactions or side-
effects, and no reduction of physical capacity or mental alertness. Lastly, they 
are suitable for long term treatment (Franz, 1977). 
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There is a variety of sources of antihypertensive agents: natural plants, cell 
extracts from animals, and synthetic drugs. There are more than 200 species of 
plants in the Encyclopedia of Chinese Drugs which have been reported to be 
hypotensive or antihypertensive. Most of species belong to 94 different families 
among different groups, such as Phaeophyta, Eumycetes, Lichens, Bryophyta, 
Gymospermae and Angiospermae. Most of these hypotensive plants are 
angiosperms. It must be noted that often only a particular part of the plant is 
active, such as leaves, rhizome, root, seed, fruit, young shoot, bark, stem, 
flower, blossom, fruit coat, root bark, stem bark, pollen, style, plural tissue, or 
shoot (Sham, 1983). Antihypertensive active components, for example, alkaloids 
and glycosides, flavonoid derivatives and polysaccharide (Sham, 1983) are 
present in certain regions of the plants, or only in certain state of the plants. 
Reserpine (methyl 11, 17 a-dimethoxy-18B-(3,4,5-trimethoxybenzoyloxy)-36, 
20a-yohimbane-16B-carboxylatean), an antihypertensive drug, is an alkaloid 
extracted from the roots of Rauwolfia serpentina and Rauwolfia vomitoria 
(Reynolds, 1989). Apart from angiosperms, mushrooms are another promising 
source of antihypertensive agents, such as Pleurotus sajor-caju and maitake 
(Kabir and Kimura, 1989). 
Muirhead et al (1981) isolated some lipids derived from kidney with potential 
antihypertensive properties. These consist of prostaglandin (a renin inhibitor), 
neutral lipid, alkyl ether analog of phosphatidylcholine which are able to decrease 
renal vascular resistance. Medullipin I, from kidney of normal rats, produces an 
antihypertensive effect in rats. The animal kidney extract contained a vasodilator 
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that suppressed sympathetic tone and had no effect in cardiac output or change 
in heart beat, thus it was a promising therapeutic agent for hypertension 
(Muirhead et al” 1991). An extract was prepared from hemolyzed erythrocytes 
of spontaneously hypertensive rats which inhibited lanthanum-resistant calcium 
uptake by aortic segments and lowered blood pressure in several models of 
hypertension (McCumbee et al” 1985). 
Classification of antihypertensive drugs 
Kaplan (1983) studied over 500 compounds which have been reported to have 
antihypertensive activity. According to their mechanisms of action, these 
compounds fall into 7 classes. They were (1) drugs interacting at a-adrenoceptor 
sites, (2) B-adrenoceptor antagonists, (3) drugs interacting with the autonomic 
nervous system by mechanisms other than (1) and (2), (4) inhibitors of the renin-
angiotensin system, (5) diuretics, (6) vasodilator antihypertensives, (7) drugs with 
miscellaneous mechanisms and/or sites of action (Appendix V). 
The autonomic nervous system (ANS) innervates the heart, blood vessels, 
viscera, and glands. Most organs innervated by the ANS receive a double supply 
of nerves, one set originates from neurons in the craniosacral regions of the 
central nervous system (CNS) to form the parasympathetic division, the other 
from the thoracolumbar regions of the spinal cord, forming the sympathetic 
division. Although the parasympathetic and sympathetic nerves often have 
opposite effects in an organ, their activity is integrated to assure the appropriate 
response of that organ. 
18 
In the case of the sympathetic division, the synapses occur in the ganglia of the 
sympathetic trunk or in the more peripheral ganglia lying along the anterior 
surface of the abdominal aorta. Most of the sympathetic postganglionic fibers are 
distributed with the spinal nerves but some enter visceral branches. The 
parasympathetic ganglia, on the other hand, commonly lie on or in the organ 
supplied (Bell, 1980). Stimulation of synapses involves the release of a chemical 
neurotransmitter. The preganglionic sympathetic nerve terminals secrete 
acetylcholine. In contrast, the postganglionic fibers of the sympathetic neurons 
secrete norepinephrine, or noradrenaline, consequently are termed adrenergic 
nerves. Acetylcholine causes blood pressure falls and bradycardia due to 
vasodilation (Rang and Dale, 1987). Most postganglionic sympathetic fibers are 
adrenergic with the exception of sympathetic cholinergic vasodilator fibers 
innervating the blood vessels of the skeletal muscles and sweat glands. All 
parasympathetic and all autonomic ganglia are cholinergic (Bell, 1980; Strand, 
1978). 
Adrenoceptors are of two types: one is a-adrenoceptors, the other is B-
adrenoceptors. a-adrenoceptors are mostly found in blood vessels, whereas B-
adrenoceptors are mainly found in hearts (Rang and Dale, 1987). A receptor is 
defined by Rang and Dale (1987) as a protein molecule which is capable of 
selectively binding a drug, hormone or neurotransmitter, thereby eliciting a 
physiological response. 
The basic mode of action of antihypertensives is to act as agonists or antagonists 
on receptors. An agonist is designated as a drug, hormone or transmitter 
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substance that elicits a cellular response when it combines with its receptors 
(Rang and Dale, 1987). For instance, the B-agonist, isoprenaline, acts almost 
entirely on B receptors and it increases the rate and force of the heart beat, causes 
skeletal muscle vasodilatation and relaxation of the bronchi and of the uterus 
(Bell, 1980). An antagonist is a drug that prevents the effect of an agonist (Rang 
and Dale, 1987). Sometimes, antagonists are therefore known as blockers. For 
example, the fi receptors activity can be blocked by a number of drugs such as 
oxprenolol, propranolol, atenolol and practolol. The discovery of practolol which 
blocks the B receptors in the heart but not those in the bronchi, and of 
salbutamol which stimulates bronchial but not cardiac B receptors, has indicated 
that there are two populations of adrenergic B receptors. These are designated B, 
in the heart, in the bronchi and vascular smooth muscle (Bell, 1980). 
In general, many antihypertensives are adrenergic inhibitory agents or 
sympathetic blocking substances. They are compounds which block the 
stimulatory action of norepinephrine. The regions that drugs may act on are 
junctions between the sympathetic nerve and the blood vessel, the junction within 
the sympathetic ganglia, and the region of the hypothalamic sympathetic center 
(Schlittler, 1967). 
Smooth muscles (except those of the gastrointestinal tract and sphincters) contract 
in response to the stimulation of ai-adrenoceptor, which results in the increase 
of the permeability of calcium ions, which then increases the concentration of 
free intracellular calcium ions. This will reinforce the contractile action of the 
muscle. Therefore, when an ai-adrenoceptor agonist is injected into tested 
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animals, the total peripheral resistance increases which would lead to an increase 
in arterial pressure (Rang and Dale, 1987). If a�adrenoceptor antagonists have 
been used, it would produce an opposite action of the agonist, lessen the 
constriction tone of the arterioles and venule and finally decrease the arterial 
pressure (Schlittler, 1967). 
a. Class one: drugs acting at a-adrenoceptor sites 
This class includes three subclasses, they are (1) mixed Ofa-adrenoceptor 
agonist and a,-adrenoceptor antagonist, (2) oti-adrenoceptor antagonist, (3) ofj-
adrenoceptor agonist, representative drugs are urapidil, prazosin, and 
clonidine respectively (Kaplan et al” 1983). 
Followed are some examples of a,-adrencx:eptor antagonists or a!-
adrenoceptor agonists. Clonidine is clinically used for treatment of 
hypertension. It acts as the peripheral presynaptic ofj-adrenoceptor agonist on 
vascular smooth muscle (Kaplan and Smith, 1981). It was observed that 
intravertebral artery administration of small doses of clonidine decreased 
blood pressure in intact chloralose anesthetized dogs. It decreased blood 
pressure in carotid sinus denervated dog. However, intravenous doses of 
clonidine in the same dogs or cats have no such depressor effect observed. 
Thus, carotid sinus denervation, a maneuver used to reflexly increase 
sympathetic tone, has been shown previously to enhance the hypotensive 
effects of centrally acting hypotensive drugs. In short, clonidine is a prototype 
of drugs that stimulate the aj-receptors in the brain stem, thereby diminishing 
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the sympathetic outflow to the vascular system (Smith and Kampine, 1990). 
Prazosin is a good antihypertensive, it decreases blood pressure without 
producing tachycardia, and produces relaxing effects on vascular smooth 
muscle through selective blockade of presynaptic aj-receptors in the 
peripheral vascular beds (Smith and Kampine, 1990). 
b. Class two: 6-adrenoceptor antagonists 
This class also includes three subclasses, they are (1) 15-adrenoceptor 
antagonist with a vasodilator component, (2) B-adrenoceptor antagonist, 
nonselective, (3) B-adrenoceptor antagonist, cardioselective (Kaplan and 
Smith, 1981). Most B-adrenoceptors are found in the heart, SA (Sinoatrial) 
node, atrial muscle, AV (Atrioventricular) node and ventricular muscle of the 
heart (Rang and Dale, 1987). Upon stimulation, they cause increases in the 
rate, force and automaticity of the heart. B-adrenoceptor antagonists or B-
adrenoceptor blockers reduce heart rate, the force of the cardiac contraction, 
and cardiac output within minutes of the intravenous administration, but blood 
pressure does not fall until a few hours later (Iriuchijima, 1982). 
In general, the sites of action of 6-adrenoceptor antagonists are mainly in 
juxtaglomerular apparatus of the kidney, heart, brain, postganglionic 
sympathetic nerve terminals, and vascular smooth muscle (Kaplan and Smith, 
1981). The mechanisms of depressor effect of the B-adrenoceptor antagonists 
are listed as follows (Kaplan and Smith, 1981): 
(1). Modulation of central blood pressure regulation 
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(2). Cardiac mechanisms: vascular adaptive changes to reduced cardiac 
output or reduced cardiac sympathetic stimulation 
(3). Inhibition of renin release (Rang and Dale, 1987) 
(4). Presynaptic inhibition of sympathetic neurotransmission 
(5). Resetting of baroreceptor 
(6). Restoration of vascular relaxant sensitivity 
(7). Effects on plasma volume 
(8). Decrease in enzymatic activity in sympathetic ganglia 
(9). Calcium antagonists: inhibiting the influx of extracellular calcium into 
the vascular smooth muscle cell 
Hydralazine, diazoxide, nitroprusside, minoxidil, dihydralazine are some 
clinically used antihypertensives (Kaplan et al, 1983; Schlittler, 1967). 
Among antihypertensives, fi-adrenoceptor antagonists are one the most 
effective drugs in the treatment of hypertension. Some are used for long-term 
treatment emergencies for they reduce the risk associated with coronary heart 
disease (Kaplan and Smith, 1981). However, the side effects of the 
adrenoceptor blockers cannot be ignored. Hydralazine will induce lupus-like 
syndrome; diazoxide causes hyperglycemia and hyperuricemia; diazoxide and 
minoxidil incite hirsutism which is excess growth of hair of normal or 
abnormal distribution (Kaplan, 1981). Hydralazine and minoxidil, 
vasodilatory agents, which relax vascular smooth muscle, cause fluid retention 
and reflex tachycardia. For this reason, they are not used alone but mainly as 
adjuncts (Smith and Kampine, 1990). 
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C, Class three: drug acting on the autonomic nervous system other than 
classes one or two 
This class contains three different groups of drugs. They are 'depleters', 
blockers and release inhibitors. Commercial products include reserpine and 
guanethidine. Reynolds (1989) explained the mode of action of the drugs. For 
instance, reserpine causes depletion of noradrenaline store in peripheral 
sympathetic nerve terminals and depletion of catecholamine and serotonin 
store in the brain, heart, and many other organs resulting in a reduction in 
blood pressure, bradycardia, and depression in the activity of central nervous 
system. The hypotensive effect is mainly due to a reduction in cardiac output 
and a reduction on peripheral resistance. Reserpine is an alkaloid obtained 
from the roots of Rauwolfla serpenta (Reynolds, 1989). 
Side effects commonly include nasal congestion, CNS symptoms including 
depression, nightmares, and symptoms of increased gastro-intestinal tract 
motility including abdominal cramps, and , at a higher dose increased gastric 
acid secretion. Higher doses may cause flushing, bradycardia, severe 
depression which may lead to suicide, and extrapyramidal effects (Reynolds, 
1989). 
d. Class four: inhibitors of the renin angiotensin system 
The class contains three subclasses. They are (1) renin inhibitors, (2) 
angiotensin II receptor antagonists, (3) angiotensin-converting enzyme 
inhibitors. These groups of drugs are especially important for those patients 
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suffered from Goldblatt hypertension that is hypertension due to the formation 
of excess renin by the ischemic kidney (Strand, 1978). 
As we know, renin acts enzymatically to cleave a decapeptide, angiotensin I, 
to angiotensin II which is known as the most powerful vasoconstrictor agent 
and a potent stimulus for the secretion of aldosterone into the circulation. 
Angiotensin can therefore increase blood pressure by its action on the adrenal 
cortex, causing increased aldosterone secretion, and/or vasoconstriction of the 
arterioles (Strand, 1978). Therefore, once abnormal secretion of renin occurs, 
it will eventually cause hypertension. The drugs belonging to this class 
usually compete with the natural substances for the active site of renin and in 
this way prevent the formation of angiotensin I (Franz, 1977). 
One the most commonly used antihypertensives is captopril, which was 
demonstrated by many studies that acute and chronic administration of 
captopril resulted in a significant reduction in blood pressure, simply by 
inhibiting the renin system (Antonaccio and Cushman, 1984). Besides, 
captopril is an effective agent in all hypertensive states and does not increase 
the heart rate or cause significant side effects (Komsuoglu et al, 1991). 
Only 0.01 to 0.04 fxg of pure synthetic captopril can inhibit angiotensin-
converting enzyme (ACE) in a variety of species. Captopril is active in 
blunting the pressor effect of angiotensin I in rats and dogs, only 20 fig of 
captopril per kg of the body weight of the rat could inhibit the pressor 
response to angiotensin by 50%. In other words, the effective dose of 
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captopril is small. Other properties of captopril make it a successful 
antihypertensive. For instance, captopril does not inhibit other enzymes such 
as chymotrypsin, trypsin, carboxypeptidase A and B and leucine amino 
peptidase. Thus, it causes fewer side effects compared with other 
antihypertensives. 
The principal mechanism of action of the captopril was enzyme inhibition. 
The compound does not interact directly with the autonomic nervous system, 
it does not block or potentiate adrenergic receptors, and does not interact with 
the central nervous system (Antonaccio, 1984). Captopril was found to 
successfully attenuate the brain injury of renovascular hypertensive survivor 
rats suffered from cerebral ischemia (Capdeville, 1990). A recent clinical 
study on captopril, reported by Gavuas (1991), showed that blood pressure 
of hypertensive patients returned to normal after taking captopril orally for 
two weeks. 
Komsuoglu et al (1991) summarized the mechanisms of action of captopril 
as follows: 
(1). Blocking the formation of angiotensin II from its precursor, thereby 
preventing its marked influence on vasomotor tone and aldosterone 
secretion. 
(2). Reducing the breakdown of tissue and plasma bradykinin, thereby 
enhancing its vasodilator effect. 
(3) Altering the metabolism of kallikrein and prostaglandin (some 
prostaglandins are vasodilatory). 
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Another successful drug which belongs to the same group is saralasin which is 
a potent angiotensin II receptor antagonist. It was found fully effective in 
lowering acute angiotensin hypertension but only partially effective during 
chronic hypertension (Smits et al” 1991). 
e. Class five: diuretics 
Subclasses include (1) those with mechanisms unknown or not well 
established, (2) thiazide-type diuretics, (3) loop diuretics, (4) potassium-
sparing diuretics, (5) aldosterone antagonist. Some commercial products of 
this class are hydrochlorothiazide, furosemide, amiloride and spironolactone 
(Kaplan, 1981). 
Thiazide, the most commonly used diuretics, lowers arterial pressure by 
blocking sodium reabsorption at the distal nephron and thus causes salt and 
water depletion. Furosemide, a less commonly used diuretic, acts primarily 
to inhibit active chloride transport at the ascending loops of Henle. Materson 
et al (1990) reported on the effectiveness of hydrochlorothiazide on 644 
patients who completed the hydrochlorothiazide titration, 375 (58.2%) were 
responders and 92.8% of these completed a 6-month maintenance period. 
With 157.6/98.5 mmHg blood pressure, they were reduced by 18.3/9.5 
mmHg with low dose hydrochlorothiazide and by 20.4/9.6 mmHg with high 
dose hydrochlorothiazide; more patients achieved goal blood pressure with the 
high dose. 
Careful attention is given to side effects, especially with longer-acting 
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diuretics, such as potassium loss, alkalosis, and elevated uric acid, glucose, 
and triglycerides. Because hypokalemia is a troublesome side effect, 
especially with longer-acting diuretics, potassium-spacing diuretics such as 
spironolactone are also sometimes used in the treatment of essential 
hypertension, and potassium supplements are often given (Nolan and Unas, 
1988). It must be noted that the treatment of hypertensive patients with 
diuretics or by salt restriction often causes a marked increase in renin 
secretion. When this occurs, the effectiveness of the therapy is greatly 
reduced or even completely negated (Guyton, 1980). 
f. Class six: vasodilator antihypertensives 
The class includes three subclasses. They are (1) those with mechanisms 
unknown or not well established, (2) prostaglandins (drugs interacting via 
arachidonic acid cascade), (3) calcium entry blockers. Examples are CI 
115,347 and nitrendipine (Kaplan, 1983). 
The primary hemodynamic effect of the calcium entry blockers is to reduce 
the total peripheral resistance with a subsequent decrease of blood pressure. 
The basic mechanism is that nitrendipine (as an example for explanation) 
selectively inhibits the depolarization-induced contraction in isolated vessels. 
Since the total resistance decreases, the arterial pressure is restored back to 
normal. Furthermore, nitrendipine is highly effective in normalizing blood 
pressure, reducing heart hypertrophy, and preventing mortality in salt-related 
hypertension, which are rather refractory to the effect of vasodilator. It is a 
satisfactory drug for antihypertensive monotherapy (Kazda et al, 1983). 
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g. other miscellaneous sites and mechanisms of action 
This group contains five different subclasses of drugs. (1) those with 
mechanisms unknown or not well established, (2) agent acting via 
nonadrenergic receptors, (3) calcium blockers/antagonists, (4) enzyme 
inhibitors, and (5) combination antihypertensives. Some representative drugs 
are nifedipine netanserin, bromolasalocid, SKF 64,139 (phenethylamine n-
methyl transferase inhibitor) (Kaplan, 1983). Sometimes antihypertensives 
are taken simultaneously to achieve better effects. Usually the effectiveness 
will be conspicuous (Franz, 1977), for example when hydralazine and 
reserpine were taken together, there will be more decrease in blood pressure 
(Schlittler, 1967). Combined drugs act at different sites of the systems 
responsible for the regulation of blood pressure, and combined drugs may 
abolish unwanted side effects (Reynolds, 1989). 
B. Mushrooms Their Medicinal Values 
I. The Straw Mushroom，Volmriella volvacea 
Introduction 
Volvariella belongs to the class Basidiomycetes, subclass Homobasidiomycetes, 
Series Hymenomycetes, Order Agaricales and Family Pluteaceae. There are over 
a hundred species, subspecies and varieties of Volvariella. Most of the cultivated 
forms of Volvariella found in Southeast Asia are members of the species 
Volvariella volvacea (Bull.ex Fr.) Sing. (Chang and Miles, 1986). These were 
found in China as early as 1822. Then they were introduced to the Philippines, 
Malaysia and other Southeast Asian countries around 1932 to 1935 (Chang, 1972). 
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In nature, V. volvacea grows on paddy straw. Thus straw mushroom has become 
the common name of Volvariella volvacea. Straw mushrooms are edible 
mushrooms of the tropics and subtropics. 
Different developmental stages of straw mushrooms 
Different stages in the development of straw mushrooms from hyphae to mature 
stage are shown in the Appendix VI, in which the "button" and "egg" stages were 
used in the present study. The straw mushroom grows rapidly at relatively high 
temperature; mycelial growth at 34 to 36�C; fruiting bodies formation at 28 to 
30�C. It is a fast growing mushroom; the time required from spawning to 
harvesting is only 8 to 10 days under favorable conditions (Chang and Miles, 
1986). 
Nutritive values 
The straw mushroom can serve as a source of dietary protein, essential amino 
acids, vitamins, and minerals and is considered to have genuine nutritional value 
(Jong and Birmingham, 1990). 
a. Protein 
V. volvacea contains relatively high crude protein content when compared with 
other mushrooms. V. volvacea contains some essential amino acids, some 
amino sugars 叫d polysaccharides with special biological activities, e.g., some 
of these can strengthen our bodily defense system (Huang, 1982). 
b. Carbohydrates and lipid 
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V. volvacea possesses high content of carbohydrates. Additionally, it contains 
all classes of lipid compounds, free fatty acids, mono-, di- and triglycerides, 
sterol, sterol esters and phospholipids. 
The fat content of V. volvacea is 5.7-10.1% which is comparatively high 
among the cereal and vegetables except oil plants, such as peanut, sesame and 
bean. Moreover, the fatty acids of straw mushroom are mainly unsaturated 
fatty acids. Different from those of saturated fatty acids, unsaturated fatty 
acids will not cause obesity and arteriosclerosis (Huang, 1982). It is also noted 
that the straw mushroom contains linoleic acid which cannot be synthesized by 
human beings. Essential fatty acids are considered to be able to cure dermatitis 
and restore the growth of young animals fed with a diet devoid of or very low 
in fat (Guthrie, 1979). Ergosterol is an important element for production of 
pro-vitamin D in the body (Breene, 1990). 
c. Minerals and vitamins 
Significant quantities of mineral salts (for example, those of phosphorus, 
sodium, potassium, calcium, and iron) and vitamins (for example, vitamins Bj, 
Bj, Bi2, C, r>2 and D4) are present in V. volvacea. These substances are vital 
for normal growth of the body. 
The nutrients are absorbed from the substrate during growth (Breene, 1990; 
Chang and Miles, 1984; Huang, 1982; Huang et al•，1985). The practice of 
using fungi as medicines has been found in the traditions of many cultures, 
past and present. The early herbalists were probably more interested in the 
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medicinal properties of fungi than in using them as food. The first Chinese 
book in medicinal substances, the Shen Nong's Herbal, dating from 2000 
years ago, recorded the beneficial effects of various fungi. In the Compendium 
of Materia Medica, Li Shih-chen of the Ming Dynasty listed more than 20 
species of the medicinal fungi (Jong and Birmingham, 1990). Furthermore, 
mushrooms have a notable place in folklore describing medicinal effects of 
various fungi throughout the world (Cochran et al” 1978). It is worth noting 
that folklore is a promising source for leads to new drugs. 
n. Mushrooms，Blood Pressure and Related Changes 
Following traditional Chinese folk remedies, decoction made with mushrooms 
have been taken to treat acute nephritis, systemic dropsy, and difficulty in 
urination (Ying et al，1987). Then medicinal and therapeutic values such as in 
prevention and treatment of cancer, viral disease, hypercholesterolemia, blood 
platelet aggregation and hypertension have been reported (Breene, 1990). 
Hypolipidemic activities 
Some edible mushrooms have been reported to be hypolipidemic. These are 
Lentinus edodes (shiitake), Agaricus bisporus (champignon), Auricularia 
polytricha (Jews-ear), Flammulina velutipes and Ganoderma sp. (Breene, 1990; 
Kaneda and Tokuda, 1966; Yasuhiro and Cochran, 1974a). Hypolipidemic 
activities here are defined as the actions of substances which are able to lower the 
levels of cholesterol, triglyceride or lipid in the blood of animals or human 
beings. Cholesterol, an alcohol lipid or sterol, is present in all animal fats. It is 
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necessary for the formation of many essential substances such as steroid 
hormones and bile salts; it is an integral part of all membranes of the body 
including myelin, which forms a protective sheath around nerve fibers (Guthrie, 
1979). Only a small population of people stores excess cholesterol inside the 
body. Some people especially in some developed countries have eaten too much 
fat. These excessive fat will be stored inside the body including blood vessels. 
Coronary disease, hypertension, atherosclerosis, diabetes and gallstones were 
highly related to cholesterol levels. 
a. Lentinus edodes (shiitake) 
Shiitake was reported to be effective in curing heart disease. It probably 
contained some active components which encouraged the excretion of 
cholesterol molecules or inhibited the absorption of cholesterol (Breene, 1990; 
Kabir and Kimura, 1989; Kaneda and Tokuda, 1964; Kaneda and Tokuda, 
1966; Tokuda and Kaneda, 1976; Tokita et al, 1972; Yashuiro and Cochran, 
1974a). 
For example, the administered cholesterol was absorbed by the intestine. The 
cholesterol molecules were then transferred to the liver in the form of 
chylomicron, a low density lipoprotein and a complex of free fatty acid and 
albumin (Conn and Stampf, 1976). After hydrolysis, the cholesterol molecules 
were re-esterified in the liver and then further transferred to the plasma in 
form of a-lipoprotein. a-lipoprotein was then transformed into B-lipoprotein 
fraction. When the rats were fed with shiitake, the transformation from a-
lipoprotein to 15-lipoprotein was faster. 
33 
Of the earlier reports in the ,70，fresh or dried shiitake were shown to reduce 
cholesterol level by 12% or 1% when taken daily for one week in human 
beings (Shinjiro and Sumiko, 1974). Yasuhiro and Cochran (1974a) reported 
the chronic hypocholesterolemic effect of shiitake in mice. The serum 
cholesterol level was significantly lowered when mice were fed with 5% 
shiitake in diet for only one week, from the original level of about 181.1 
tng% to 129.3 mg%. Another group fed with 5% shiitake for 14 months, the 
serum level was lowered from about 149 tng% to 130 mg%. Apart from the 
cholesterol level, the mushroom was able to lower lipid levels in rats as 
reported by Tatsuo (1974). In another study, rats were fed with or without 
exogenous cholesterol, with or without ground dried shiitake mushroom (5%) 
ad libitum for 10 weeks. The total plasma cholesterol was significantly 
reduced in cholesterol fed rats which were fed dried mushroom at the same 
time (Kaneda and Tokuda, 1966). 
As shown in the Table 1, the total plasma and free cholesterol levels of group 
CM were remarkably lowered than that of group C. Shiitake was able to 
lower the level of cholesterol in liver. In this report, a group of rats fed with 
ergosterol was included because shiitake was rich in ergosterol (approximately 
0.3% in dry matter), and ergosterol was reported to show similar effect of 
phytosterols against plasma cholesterol in rats (Kaneda and Tokuda, 1966). 
The results showed that ergosterol did not reduce total cholesterol levels, 
suggesting that it was not the active component in reducing cholesterol levels 
in blood and liver. 
34 
Kaneda and Tokuda reported (1966) that fractionation on the cholesterol-
lowering principle in shiitake yielded two active fractions, first, a water-
soluble fraction and, second, a 30% ethanol-soluble fraction. It was 
demonstrated that the active component responsible for hypolipidemic activity 
was eritadenine (Breene, 1990; Tatsuo, 1974; Huang, 1987). Eritadenine was 
also called lentysin with chemical formula 2(R), 3(R)-dihydroxy-4(9-adenyl)-
























































































































































































































































b. Ganoderma sp. (mannentake) and other mushrooms 
The physiological effect of mannentake was hypocholesterolemia (Breene, 
1990). Kabir and Kimura (1989) showed that the total plasma cholesterol 
level was significantly lowered in SHR fed 5% mannentake for 8 weeks. 
Mannentake was probably an inhibitor in cholesterol synthesis and/or 
accelerator in cholesterol metabolism. 
Agaricus bisporus (champignon), Volvariella volvacea (straw mushroom), and 
Flamminula velutipes were also reported to lower the cholesterol levels 
(Huang, 1987). 
Hypotensive activity 
I Some edible mushrooms, Tremella Juciformis, Flammulina velutipes, Hericiim 
crimceus, Agaricus bisporus, Pleurotus ostreatus and Lentinus edodes were 
reported to be hypotensive. Agaricus bisporus，has especially been used clinically 
to lower blood pressure in China (Huang, 1987). Chronic ingestion of Pleurotus 
sajur-caju had an excellent effect on controlling blood pressure especially in 
hypertensive patients. Kabir and Kimura (1989) reported that Ganoderma lucidum 
was a folk medicine which had been used to treat hypertension. 
a. Pleurotus sajor-caju 
Tarn et al (1986) reported that an aqueous extract of Pleurotus sajor-caju has 
a hypotensive effect in rats. A typical dose of 25 mg/kg of the extract 
decreased the mean arterial pressure from 110 mmHg to 70 mmHg. This 
effect might be due to the presence of vasoactive ingredients which are able 
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to decrease total peripheral resistance by dilating blood vessels. 
b. Giifola frondosa (maitake) 
The fruit body of Grifola frondosa was confirmed to contain a substance with 
blood pressure-lowering activity. When powdered fruit body of maitake was 
given orally to spontaneously hypertensive rats (SHR), blood pressure was 
reduced. Blood pressure-lowering activity was found in ether-soluble fraction. 
When the ether-soluble fraction was further separated into acetone-soluble and 
acetone-insoluble fractions, a blood pressure reduction of about 45 mmHg 
was observed after the administration of ether soluble-acetone soluble 
fraction, while the reduction was about 65 mmHg by the ether soluble-acetone 
insoluble fraction. 
•1 1 
In thin layer chromatography analysis of the ES-AP fraction with chloroform-
methanol-water (130:50:8) solvent, 8 subfractions were detected. When each 
subfraction was collected and extracted with a chloroform-methanol mixture 
！ 
(1:1)； the most potent activity was found in the subfraction which was 
detected on the spot of 1^=55.3. When antihypertensive agents were 
examined in combination with maitake, a hypotensive effect was observed in 
the presence of reserpine. This suggested that the blood pressure-lowering 
effect of maitake was brought about by a mechanism other than sympatholytic 
action (Kyoko et al, 1988). 
38 
MATERIALS AND METHODS 
A. Basic Preparative Procedures 
I. Preparation of Straw Mushroom Extract (SME) 
The "button" or the "egg" stages of straw mushroom, V, volvacea were 
provided from the Mushroom House of the Chinese University of Hong Kong. 
They were weighed and washed, and 100 g of them was mixed with 100 ml of 
cold distilled water and homogenized in a blender for 5 minutes. The 
homogenate was either boiled for an hour to produce boiled straw mushroom 
homogenate or not boiled to produce unboiled straw mushroom homogenate. 
！ 
The boiled or unboiled homogenate was filtered through cotton absorbent gauze 
(Dah Tung Factory, China) and then centrifuged at 8000 rpm (Sorvall 
instruments at 4°C) for 20 minutes. The supernatant was lyophilized to produce 
dry powdered form. About 32 g of dry lyophilized straw mushroom extract was 
produced from 1000 g of fresh straw mushroom. 
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f . 
n . Purification of SME by Dialysis 
Boiled aqueous straw mushroom extract (SME) was further dialyzed against 
water. SME (10 g) was dissolved in 100 ml of distilled water. The solution was 
put into four dialysis tubes (Sigma, with a cutoff point of 12000) with 
dimensions of 33 mm and 150 mm. Both ends of the tube were tied firmly with 
thread to prevent leakage. These tubes were then placed in 1 L distilled water 
for 24 hours at room temperature. Stirring was provided to make sure the 
dialysis was complete. 
The tubing retained most proteins and other substances of molecular weight 
12000 or greater. Thus, the retente was collected and then further lyophilized to 
dry powder form. The freeze dried brown residue was weighed. This dialyzed 
and lyophilized fraction with molecular weight 12000 or greater was designated, 
in short DUL12000. Substances with molecular weight less than 12000 would 
pass through the dialysis tubing into distilled water. The dialysate was also 
further lyophilized to powder form and designated as DLL12000. These two 
fractions, DUL12000 and DLL12000, were used for further experiments. 
In view of activity detected, the sample DLL12000 was further dialyzed (with 
a cutoff point of 8000) into two fractions. The methodology was similar to the 
previous description, so that the two samples DUL8000 (MW between 8000 and 
12000) and DLL8000 (MW below 8000) were obtained. 
n i . Preparation for In vivo Blood Pressure Measurement in Rats 
Male Sprague-Dawley rats weighing 280 to 350 g, provided from the Animal 
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House of the Chinese University of Hong Kong, were anaesthetized with sodium 
pentobarbital (50 mg/kg of body weight) by i.p. injection. When the tested 
animal was unwitting, it was fixed on a surgical dissection board lying on its 
back. An incision was made from lower jaw to upper part of thorax. The trachea 
was then exposed by separating the sternohyoid muscle, and was cannulated with 
a trachea cannula to facilitate spontaneous respiration. The diameter of the tube 
for cannulation should be as close to that of the rat's trachea as possible. 
The tissue around the left carotid artery was cleared and a segment of the vessel 
was exposed. A ligature was made on the anterior region of the vessel, while the 
posterior was clamped by a blood vessel clamp. A small cut with a pair of 
microdissecting scissors was made just posterior to the ligature and a 
polyethylene tubing PE-50 cannula filled with heparinized saline (0.0592 g 
j 
I heparin dissolved in 1 L of 0.9% saline or 10000 units per liter) was inserted 
and secured with surgical thread. The clamp was released when the cannulation 
was done. The cannula was connected to a pressure transducer (Narco, P-IOOB) 
and a MK-III Narco physiograph (Narco Instrument, Texas) for blood pressure 
recording. The external jugular vein was cannulated with polyethylene tubing 
PE-50 in a similar way and connected to a syringe for intravenous injection. 
The total blood volume of a rat (280 to 320 g) is around 25 ml. Therefore, the 
amount of substances injected into the body cannot be more than 5 ml, otherwise 
the normal blood composition will be adversely upset. 
IV. Preparation of Right Atrium for In vitro Studies 
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Male rats weighing 280 to 350 g were killed by cervical dislocation. An incision 
was made on the abdominal skin and the underlying muscle layer. Another 
incision was made on the diaphragm and the heart was uncovered. The entire 
heart was excised rapidly and placed in 100 ml of Krebs-Henseleit solution (K-H 
solution: NaCl, 115 mM; KCl, 5 mM; CaClj, 2.1 mM; NaHCO，，25 mM; 
NaH2P04, 1.2 mM; MgSO*, 1.2 mM; glucose 11 mM) aerated with 95% O2 and 
5% CO2. 
The right atrium was isolated and transferred to another petri dish with fresh K-H 
solution which was aerated continuously. The ends of contraction axis of the 
atrial tissue were tied by silk threads and suspended inside a tissue chamber 
containing 10 ml of K-H solution aerated continuously at 37�C. During tying up 
the silk thread, a round loop or one free end of the silk should be made in order 
j 
to hook up the tissue to a fixed position in the organ bath. The other end of the 
thread was connected to a force displacement transducer (Narco Myograph F-60). 
Isometric contractions were recorded on a Narco Physiograph (MK-III). 
The atrial tissue was under a resting tension of 1 g, and equilibrated for 30 
minutes before any testing. SME or other substances were applied directly into 
the chamber and cumulative dose responses were obtained (Sham, 1983). 
V. Preparation of Artery Strip for In vitro Studies 
Male rats (280-300 g) were killed by cervical dislocation. The ventral tail artery 
was isolated and placed into K-H solution which was aerated with 95% O2 and 
5% CO2. Connective and fat tissues were removed. Strips (2 cm) were cut under 
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a dissecting microscope at 4 5 � t o produce helical strips. The helical strips were 
tied at both ends and then suspended in the 10 ml tissue chamber which was 
aeratfsd continuously with O2 and CO2 at 37�C. 
One end with a round loop was hooked to the bottom of the tissue chamber, the 
other end was connected to a force displacement transducer (Narco Myograph F-
60). Isometric contractions were recorded on a Narco Polygraph (MK-III). 
Before exposure to drugs, the helical strip was equilibrated for 60 minutes under 
a resting tension of 0.7 g. KCl (60 mM) was used to test the helical strip. An 
acceptable strip should develop tension between 0.5 to 1.0 g, and tests with KCl 
should be performed three times. After each test, the strip should be washed with 
K-H solution several times and given 10 minutes for equilibration. When the 
!' tension was steady, SME and other drugs were tested respectively (Sham, 1983). 
1 
Six successful preparations were used in each test. 
•j 
B. Experiments Done 
Experiment 1. Toxicity of SME (Results shown in Table 2) 
Male Sprague-Dawley rats weighing 280 to 350 g were provided from the 
University Animal House of the Chinese University of Hong Kong. They were 
divided into 8 groups of 4 rats each. They were fasted for 12 hours before testing 
with the intraperitoneal administration of unboiled and boiled SME respectively. 
Different doses of unboiled SME and boiled SME were injected i.p. • Their lethal 
time was then recorded, as calculated from the time of injection. The tested 
animals were defined as dead when no breathing was observed, and were defined 
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as alive if they were still alive 24 hours after injection. 
Experiment 2. Hypotensive Effect of SME and Dialyzed Samples 
a: Single-dose response curve (Results shown in Figure lb) 
Rats were prepared for blood pressure measurement (Refer to A.III. 
Preparation for in vivo blood pressure measurement in rats for details). 
After a 1-2 minutes period of equilibration, a bolus injection of saline (0.3 
ml) was given to check the stability of blood pressure. ( N.B. further 
testings were done only if there was no change in blood pressure when 
saline was administered). A dose of SME was administered 1-2 minutes 
after the application of saline, and the change in the mean arterial blood 
pressure (MAP) was recorded. (N.B. SME dissolved in 0.1 ml of saline 
was i.v. injected via the cannula applied and this was followed by 0.2 ml 
•！ 
j of saline which flushed all substances tested inside the cannula to the blood 
stream). When the MAP returned to the original blood pressure, another 
dose of SME (0.5, 5, 10, 20, 40, 80 and 120 mg/kg respectively) was 
applied again. If the blood pressure could not return to the original and/or 
stayed at a higher value, the tested animal would not be used for further 
'single-dose response test’ experiments. 
j “ 
b: Cumulative-dose response curve (Results shown in Figure 2 for SME, 
Figure 18 for DUL12000 and DLL12000, Figure 19 for DLL12000, 
Figures 27-32 for DUL8000 and DLL8000) 
Rats were prepared for blood pressure measurement. The basic 
methodology was similar to the above experiment (experiment 2a) except 
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there was no rinse between doses of SME or its dialyzed fractions 
(DUL12000, DLL12000, DUL8000 and DLL8000). Once the blood 
pressure was stable, another dose was applied. For example, 0.5 mg/kg 
of SME or dialyzed sample was i.v. injected, once the MAP was steady 
and noted, 4.5 mg/kg was injected through the same route again. The 
second dose of SME would be 5 mg/kg. No saline was injected between 
0.5 mg/kg and 4.5 mg/kg. Thus, for individual doses of 0.5, 4.5, 5, 10, 
20, 40, 40 mg/kg injected, these would yield cumulative doses of 0.5, 5, 
10, 20 40, 80 and 120 mg SME/kg body weight respectively. 
c: Double-dose response curve (Results shown in Figure 3) 
SD rats were prepared for blood pressure measurement. A dose of SME 
(10, 20, 40, 80 and 120 powder mg/kg body weight) was injected, the 
] 
change in MAP was noted. When MAP was steady, the same dose of 
I 
SME was applied again to check for tachyphylaxis. 
1 
Experiment 3. Pharmacological Antagonist Studies I 
a: Autonomic ganglion transmission (Results shown in Figure 4) 
Male SD rats were prepared for blood pressure measurement. Both test 
drugs and SME were first given through external jugular vein. The dose 
of SME was 25 mg dry weight/kg body weight. A bolus injection of SME 
was given. The MAP was noted. It served as the control. Hexamethonium 
(Sigma), an autonomic ganglion blocker, was then injected iv. at a dose 
of 10 mg/kg body weight. After the blood pressure was depressed under 
the blocker and steady, a bolus injection of SME was given again. The 
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change in MAP was recorded, which was then compared with the control 
(Sham, 1983). 
b: Alpha-adrenergic activity (Results shown in Figure 5) 
Male SD rats were prepared for blood pressure measurement. A bolus 
injection of SME was given and the MAP change observed served as a 
control. This was followed by an injection of methoxamine (50 /xg/kg, 
Burroughs-Wellcome) which is an agonist of a-adrenoceptor and the MAP 
was noted. The blockade of a-adrenoceptor was performed by 
phentolamine (2 mg/kg, Ciba). As soon as the MAP was steady, the same 
dose of methoxamine was given again to ensure the blockade of a-
adrenoceptor. If the pressor effect was blocked, a test dose of SME was 
then given immediately. The MAP changes were recorded. 
c: Beta-adrenergic activity (Results shown in Figure 6) 
The procedure was similar to that in testing a-adrenergic activity. Now 
the B-agonistwas isoproterenol (1.2 jug/kg, Sigma), and the antagonist was 
propranolol (2 mg/kg, Sigma). 
d: Cholinergic activity (Results shown in Figure 7) 
The procedure was similar to the adrenergic blockade. Acetylcholine acts 
as the neurotransmitter in the peripheral nervous system. Its direct effect 
is vasodilation. It served as an agonist at a dose of 2 ixglVg (Merck). Rats 
were then treated with 2 mg/kg atropine (Sigma), an acetylcholine 
antagonist. The effectiveness of the muscarinic receptor blockade was 
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verified by a diminished response induced by same dose of acetylcholine. 
Changes in MAP were compared with the control. 
e: Histaminergic activity: (Results shown in Figure 8) 
The procedure was similar to the adrenergic blockade. A bolus injection 
of histamine (Sigma), a powerful vasodepressor was given intravenously 
at a dose of 2 pig/kg to the rat to induce the hypotensive response. 
Pyrilamine and cimetidine, corresponding to Hi and Hj receptor blocker 
respectively, were injected simultaneously at a dose of 15 mg/kg each. 
The blockade was checked by introducing the same dose of histamine. If 
the action of histamine was blocked, a dose of SME was then given 
immediately. 
• 
j Experiment 4. Effect of Autonomic Ganglion Blocker and Alpha Blocker on the i 1 i 
Hypotensive Changes Induced by SME 
a: Effect of hexamethonium on hypotensive changes induced by SME 
i (Results shown in Figure 9) 
j i 
！ 
In order to see if the effect of hexamethonium on SME induced pressure 
change (shown earlier in 3a) was dose dependent. Male SD rats were 
prepared for blood pressure measurement. A bolus injection of SME (40 
mg/kg) was given (served as the control), and the change in MAP was 
recorded. An injection of hexamethonium (started from low concentration, 
0.3 mg/kg, 0.8 mg/kg and 3 mg/kg respectively) was given and followed 
by SME (40 mg/kg). The MAP changes in different concentrations of 
hexamethonium were then compared with the control. 
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b: Effect of phentolamine on hypotensive changes induced by SME (Results 
shown in Figure 10) 
The preparation and rationale of this study were similar as in experiment 
4a except phentolamine was used instead of hexamethonium. The 
concentration of phentolamine was 0.3 mg/kg, 1 mg/kg or 2 mg/kg 
respectively. 
Experiment 5. Study on Renin-Angiotensin and Kinin Systems: Effect of 
captopril infusion on the action of SME (Results shown in 
Figures 11 & 12) 
Male SD rats were prepared for blood pressure measurement. In addition, 
another cannulation was made at the femoral vein for infusion. The possible 
interaction between the hypotensive action of SME and the renin-angiotensin and 
i 
the kinin systems were studied using a converting enzyme inhibitor, captopril 
(SQ14, 225). The responses of the rat to SME (20 mg/kg) were recorded. An 
effective dose of angiotensin I (40 ng/kg, Sigma) or bradykinin (40 ng/kg, 
Sigma) was injected and then followed by captopril infusion via the femoral vein 
(10 /xg/min/kg, SKF) for 30 minutes at 0.077 ml/min. The MAP change induced 
I 
by SME was compared with MAP before infusion of captopril. Apart from MAP, 
the time required for 75% recovery to the original MAP was noted and this 
served as another indicator for the effectiveness of captopril. 
Experiment 6. Urinary and Sodium Excretion in Water-loaded Rats (Results 
shown in Figures 13 & 14) 
To study the effect of SME on the kidney, male rats were anaesthetized with 
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sodium pentobarbital (50 mg/kg of body weight). When the rat was unconscious, 
it was placed dorsally and infused through a tail vein with 10 mM NaCl in 5% 
glucose at a rate of 0.2 ml per minute for about 2 hours (Li, 1989). After the 
emergence of the first drop of urine in about 30 minutes, urine sample was 
collected as control in a 20 minute period. In the following 20 minutes, infusion 
of either SME or ANP (all drugs dissolved in 10 mM NaCl in 5% glucose) was 
performed at the same rate and in the same rat. The urine sample was again 
collected. The volume of urine sample was measured, then were stored under -
20�C to determine their sodium ion concentration by atomic absorption 
spectrophotometry. 
Experiment 7. Chronotropic and Inotropic Studies of Isolated Right Atria 
a: Effects of SME (Results shown in Figures 15 & 16) 
i 
Right atria of SD rats were prepared. Four doses 3, 30, 100 and 3000 mg 
of SME/L of K-H solution in organ bath, were added beginning with the 
smallest dose. When the atrial beat and atrial tension were steady after the 
first dose,the next higher dose was applied immediately and so on. 
Chronotropic and inotropic response curves were then obtained. 
b： The chronotropic effects of DLL12000 in different groups of rats (Results 
shown in Figure 20) 
Isolated atria were prepared. The chronotropic effects of DLL12000 (2, 
20, 200, 800, 2000 mg/L) were studied in male SD rats. 
c: The inotropic effects of DLL12000 (Results shown in Figure 21) 
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The methodology was basically similar to Experiment 7b except the 
inotropic response towards DLL12000 of the isolated atria was measured. 
d: The chronotropic effects ofDULSOOO on different groups of rats (Results 
shown in Figure 33, see also Figures 39, 40 & 41) 
Isolated atria were prepared. The chronotropic effects ofDULSOOO (3, 30’ 
100, 3000 mg/L) were studied in male, female, young male SD rats (Male 
and female SHR, weighing 200 to 250 g were provided by the Animal 
House of Hong Kong University) as well as in female SHR. 
e: The inotropic effects of DUL8000 (Results shown in Figure 34, see also 
Figures 42, 43 & 44) 
The methodology was basically similar to Experiment 7d except the i 
j 
inotropic effect of the isolated atria was studied and measured. 
i 
f: The chronotropic effects of DLL8000 (Results shown in Figure 36, see 
also Figures 39, 40 & 41) 
The methodology employed was exactly the same when compared with the 
above experiment except the sample tested was DLL8000. 
g: The inotropic effects of DLL8000 (Results shown in Figure 37, see also 
Figures 42, 43 & 44) 
The experimental procedures were similar to the above experiment. 
Experiment 8. Contractile Responses of SME & Its Dialyzed Samples on Rat 
Tail Artery Strips 
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a: Cumulative dose effect of SME (Results shown in Figure 17) 
Rat tail artery strips were prepared. Four doses (10, 100, 1000 and 3400 
mg/L) of SME were tested, starting with the smallest dose. When the 
tension developed was steady and noted. The tested sample was washed 
with K-H solution several times and equilibrated for 10 minutes before the 
application of other substances. 
b: Effect of DLL12000 (Results shown in Figure 22) 
The experimental protocol was similar to the above experiment 8a. 
c： Effect of DUL8000 (Results shown in Figure 35, see also Figures 45, 46 
& 47) 
The experimental procedures were similar to the above experiment 8a. 
d： Effect of DLLSOOO (Results shown in Figure 38, see also Figures 45, 46 
& 47) 
The experimental procedures were similar to the above experiment 8a. 
Experiment 9. Effect of Adrenergic Blockers in SME Preconstricted Strips 
a: The relaxation effect of adrenergic blockers (Results shown in Figures 23 
& 24) 
To examine the relaxing effect on tonic contraction, rat tail artery strips 
were prepared. To stimulate contraction of the male rat tail artery strip, 
SME (3.4 g/L) was added. Once the tension levelled off, a small dose 
(0.02 mg/L) of phentolamine or propranolol was added. Once the tension 
levelled off again, higher doses ( 0.2, 2.0, 20 mg/L ) were added again 
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and so on. 
b： Effect of adrenergic blockers in SME stimulation strips (Results shown in 
Figures 25 & 26) 
To examine the inhibitory effect on phasic contraction, helical strips of 
male rat tail arteries were prepared. A dose of SME (3.4 g/L) was added 
to stimulate the strip, the steady tension developed was recorded which 
served as the control. Having rinsed for several times and equilibrated for 
40 minutes, the strip was ready to be tested again. A blocker of 0.02 
mg/L (phentolamine or propranolol) was added and immediately followed 
by SME (3.4 g/L). The tensions developed prior and after the injection of 
the blocker were compared. Different doses of the blocker were tested 
(0.2, 2, 20 mg/L). 
I i 
Experiment 10. Acute Oral Effect of DUL8000 and DLL8000 from SME on 
I Blood Pressure (Results shown in Figure 48) 1 I I 
Male Sprague-Dawley rats weighing 280 to 320 g were used in the experiment. 
The animals were divided into 2 groups. Group 1 was given DUL8000, while 
group 2 was given DLLSOOO. Each group was subdivided into 3 groups (4 rats 
for a subgroup) and fed with different doses of either DUL8000 or DLLSOOO 
(subgroup 1, 4 mg/kg; subgroup 2, 40 mg/kg and subgroup 3, 400 mg/kg 
respectively). When the rat was anaesthetized and had fallen unconscious, 
distilled water was fed orally through oral tubes (the MAP was measured which 
served as the control) and the rat was equilibrated for thirty minutes. When MAP 
became steady, a dose of DUL8000 or DLLSOOO was fed, then the MAP was 
52 
recorded. 
Experiment 11. Chronic Oral Effect of SME on Blood Pressure, Total Free 
Cholesterol and Triglyceride Levels (Results shown in Figure 
49) 
Male Sprague-Dawley rats of about 16 weeks old, weighing 280 to 330 g were 
used for the experiment. The animals were divided into 4 groups (6 rats per 
group). Each group was given different amount of SME solution daily for 8 
weeks, (group 1, 0 g/kg: group 2, 4 mg/kg; group 3, 40 mg/kg; group 4, 400 
mg/kg body weight). SME solution was fed through oral tubes at 11:00 a.m. 
every day. Chow diet and tap water were available ad libitum. 
The animals were housed throughout the experiment in stainless steel, wire-
bottom cages at room temperature with 12-h light/dark cycle. Their body weights 
were measured every week. After the 8-week period experiment, the animals 
were starved overnight, their blood pressure were measured and then sacrificed. 
Their sera were collected and stored under -20°C for later measurement of free 
cholesterol and triglyceride levels. 
Measurement of total free serum cholesterol and triglyceride levels: 
Free total serum cholesterol was measured by an assay kit (Sigma Diagnostics, 
procedure no. 352) and total serum triglyceride was measured by an assay kit 
(Sigma Diagnostics, catalog no. 336-10). 
The manual procedure of measurement of serum cholesterol level bv the assay 
kit (Sigma^ was as follows: 
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1. Cholesterol reagent containing cholesterol oxidase, cholesterol esterase, 
peroxidase, 4-aminoantipyrine, p-hydroxybenzenesulfonate, buffer, and 
nonreactive stabilizers and filers, was dissolved in distilled water. 
2. Spectrophotometer was set at 500 nm. 
3. The reagent was warmed to assay temperature (3TC). 
4. A series of tubes for blank, calibrator, control, and samples were set up. 
5. 1 ml of reagent was pipetted into each tube. 
6. 0.01 ml deionized water (blank) was added, calibrator, control and sample 
to appropriately labelled tubes. Mixed by gentle inversion. 
7. Tubes were incubated for 5 minutes at 3 7 � C 
8. Absorbance (A) of all tubes were read and recorded at 500 nm. Readings 
must be completed within 30 minutes after end of incubation time. 
9. To calculate total cholesterol in sample: 





The manual procedure of measurement of total se^im triglyceride level was as 
follows: 
1. The triglyceride reagent, containing ATP, NAD, magnesium ions, INT, 
glycerol kinase, G-l-PDH, and buffer, was diluted according to the 
instruction on the bottle of the reagent. 
2. A series of test tubes were labelled for the blank, calibrator and for each test. 
3. 1.0 ml triglyceride reagent was pipetted into each tube. 
4. 0.01 ml of deionized water was added into reagent blank tube and mixed. 
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5. At timed intervals, 0.01 ml of calibrator or test samples was added to the 
appropriate tubes and mixed. 
6. All tubes were incubated for 18 minutes at room temperature. 
7. Absorbance (A) of the blank, calibrator and each test were read and recorded 
at 500 nm versus water as reference. (The color was stable for 1 hour) 
8. To determine triglyceride concentration (mg/Dl) of a sample: 
Triglyceride level = (A^^ - AwaJ / (Ac—tor • AwaJ x concentration of 
calibrator (given) 
C. Statistics 
All data are expressed in Mean 土 SEM. Tests of significance were performed using 
the Student's t test (Sigmaplot 4.1) or the Single Factor Analysis of Variance 
(ANOVA) (Minitab 4.1), where applicable. Whenever p values were less than 0.05, 
•t ] 
the difference would be accepted as being significant. The ED50 of the dose-response 
curves were calculated according to Fleming et al (1972). 
Where ANOVA results are presented, the null hypothesis, 
Ho: No statistically significant difference found among multiple groups, 
will be rejected when F^a丨 > Fju, and will not be rejected otherwise. 
55 
RESULTS 
About 32 g lyophilized powder of SME was extracted from 1000 g of fresh straw 
mushroom. Two types of straw mushroom extract (SME) were produced: One was i -
boiled SME, the other was unboiled SME. 
A. Toxicity of Straw Mushroom Extract (SME) 
The lethal toxicity dosages of boiled and unboiled SME are shown in Table 2. Boiled 
SME did not kill rats up to a concentration of 800 mg/kg, while as little as 10 mg/kg 
of unboiled SME caused death of rats. Only boiled SME (SME) was used for further 
experiments. 
B. Effects of SME in Normotensive Rats 
I, Blood Pressure Changes 
Upon intravenous injection of SME, an immediate hypotensive response was 
observed and this was followed by an increase in blood pressure. All these 
occurred within 70 seconds and were designated as "immediate response". The 
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third phase which followed was hypotensive response which was described as the 
"succeeding hypotensive response" as shown in Figure la. It was fairly stable and 
lasted over one minute before the blood pressure returned to the original level. 
This last response was regarded as the hypotensive response of SME. 
Table 2. The toxicity test of boiled and unboiled SME 
p ^ S S j j Q j ^ S S S S S S S S S B S S S S S S S S B ^ S ^ S S ^ ^ S S ^ S S S S S ^ S S ^ ^ ^ ^ B S S 
Boiled SME Unboiled SME 
Dose Lethal Time Lethal Time 
(mg/kg)' m (hr) 
800 - 0.5 土 0.广 
2 0 0 ； 1.0 土 0.2 
80 - 1.0 土 0.3 
40 - 2.0 士 0.3 
30 - 4.0 士 0.4 
2 0 - 12.0 士 1.2 
10 - 14.0 土 0.8 
I 8 ： -
i . 
i 
t I , 
* Dosage was administered orally in mg dry weight per kg body weight. 
- R a t s survived longer than 24 hours after administration of SME. 
** Data are mean土SEM (n=4). 
SME produced significant changes in MAP (Figure lb: p < 0.001, F,^=6.12, 
F彻=2.62; Figure 2: p<0.0005, Fe.i=16.59, F彻=2.45) and the hypotensive 
changes were dose-dependent in normotensive rats. The ED50, the dose required 
to produce half the maximal response, was about 15 to 25 mg/kg based on 
Figures lb and 2. Tachyphylaxis, defined as a decrease in the antihypertensive 
effect when SME is repeatedly infused into the same rat (Tarn et al., 1986), was 
only noticeable at the high dose (120 mg/kg, Figure 3). In this case, the MAP 
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of first infection and second injection was statistically different (p<0.05). 
n . Pharmacological Antagonists Studies 
Figure 4 demonstrates that the pretreatment with autonomic ganglionic blocker 
(hexamethonium, 10 mg/kg) could block SME-induced decrease in MAP in 
anesthetized normotensive rats. The depressor effect of SME was 14.2 土 2.0 
mmHg which served as the control. When the rat was injected with 
hexamethonium (10 mg/kg), the MAP became -45 土 10 mmHg. SME was 
given again, MAP was -3 土 1 mmHg which was significantly different from 
the control (p<0.05). 
The possible involvement of a-adrenoceptors in SME mediated MAP changes 
were studied with phentolamine (2 mg/kg) and methoxamine (100 /xg/kg, Figure 
5). A test dose SME produced an immediate decrease in MAP of 14 土 2 
mmHg. When the same rat was treated with methoxamine, the MAP was 
increased to 54 土 5 mmHg. In the presence of phentolamine, the MAP increase 
was reduced to 2.0 土 0.5 mmHg. When SME was then given, the MAP was 
>0.2 土 0.2 mmHg which was significantly different from the MAP before 
I 
I , 
application of phentolamine (p<0.05). This suggested that the depressor effect 
of SME was related to a-adrenergic activity. 
losproterenol (1.2 /ng/kg) produced a decrease in MAP of 37 士 8 mmHg. In 
the presence of propranolol, it produced a drop of pressure 6 土 1 mmHg. SME 
produced a decrease in MAP of 11 ± 3 mmHg which was not a significant 
decrease compared with the control (Figure 6). Thus, the results suggested that 
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the hypotensive action was not mediated through B-adrenoceptor receptors. 
In the presence of atropine (2 mg/kg), the MAP induced by acetylcholine 
diminished the MAP from -32 土 6 mmHg to -4 土 1 mmHg. Thereafter, the 
injection of SME produced a hypotensive response of 11 土 4 mmHg which was 
not significantly different from the control group (Figure 7). These results 
indicated that the hypotensive action of SME was not mediated through 
muscarinic (cholinergic) receptors. 
When both pyrilamine (15 mg/kg, Hl-receptor blocker) and cimetidine (15 
mg/kg, H2-receptor blocker) were given simultaneously, the hypotensive action 
induced by histamine (2 mg/kg) diminished significantly from 18 土 3 to 6 土 
1 mmHg (p<0.05) as shown in Figure 8. With pretreatment of the same rat 
with pyrilamine and cimetidine simultaneously, the hypotensive response of 
； I “ ！ SME was reduced significantly from 14.2 土 2.0 mmHg to 1 土 1 mmHg 
i 
I (p < 0.05). These results suggested that the hypotensive action of SME may be 
！ . 
i mediated through histaminergic activity. 
I 
The hypotensive action of SME via the autonomic ganglionic system was 
further supported by data shown in Figure 9. Rats were given different doses 
(0.1 mg/kg, 1 mg/kg , 3 mg/kg) of hexamethonium. After the MAP was steady 
and noted, SME (40 mg/kg) was applied. Results showed that MAP changes by 
SME were significantly different after application different doses of 
hexamethonium (p<0.025, F^ ^丨=3.84, ?彻=3.29). Furthermore, the greater the 
dose of hexamethonium was applied, the smaller the depressor-effect was 
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produced by SME. Figure 10 demonstrates that the depressor effect of SME 
was mediated through a-adrenoceptor receptor because phenotolamine applied 
produced statistically difference on hypotensive changes induced by SME 
(p<0.0025, F«a=6.64, F彻=2.96). For an increase in the dose of 
phentolamine, there was a corresponding decrease in depressor effect of SME. 
HL Converting Enzyme Activity 
The effectiveness of captopril, an angiotensin-converting enzyme (ACE) 
inhibitor, was observed in the MAP responses of the rat to angiotensin I and 
bradykinin (Figures 11 and 12). When the tested animals were treated with 
captopril, MAP of rat treated with angiotensin I was significant reduced. MAP 
induced by angiotensin before and after infusion of captopril were 34 士 8 
mmHg and 2 士 4 mmHg, a significant reduction in MAP (p<0.05). A similar 
phenomenon was observed in case of SME. The depressor effect of SME was 
changed from -49 士 11 mmHg to -7 土 1 mmHg. These results suggested that 
I captopril infusion affected the hypotensive effect of SME, an effect observed 
i 
which might be comparable to bradykinin. The duration of 75% recovery of 
MAP, due to SME in the presence of captopril, was shorter as expected, but 
the difference are not statistically significant as shown in Figure 12. The 
duration of 75% recovery of MAP for bradykinin was significantly increased 
from 1.2 土 0.2 minutes to 3.6 土 1.0 minutes (p<0.05). 
IV. Urinary and Sodium Excretion 
SME, at infusion rates of 0.3, 1 and 3 mg/min produced no significant 
differences in urine and sodium excretion compared with the control in the 
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water-loaded rats as shown in Figures 13 and 14. When a natriuretic hormone 
ANP (atrial natriuretic peptide) was infused at 500 ng/min for 20 minutes, both 
urine and sodium excretion were significantly increased (P<0.05). 
V. In Vitro Arterial and Cardiac Effects 
SME acted directly on the atria and produced a significant chronotropic effect 
(p<0.005, Fe.,= 15.77, Fau=2.42). SME increased the atrial rate from 324 土 
18 to 450 士 12 beat/min as the cumulative dose of SME increased to 300 
mg/L. However, as doses increased further (1800 mg/L to 4800 mg/L), atrial 
rates decreased (396 士 18 to 240 土 42 beat/min) (Figure 15). The contractile 
force of the isolated right atrium to SME varied according to different 
concentrations of SME. These differences were not statistically significant. It 
increased gradually from 0 to 300 mg/L, and decreased from 300 to 1000 mg/L 
and increased again from 1000 to 3400 mg/L (Figure 16). 
j 
I SME produced significant changes in contractile force of tail artery strips 
！ 
(p<0.0005, 16.86, Fdi,=2.84). Furthermore, the contractile force of tail 
artery to SME in rats was dose-dependent (Figure 17). 
The tension resulted from potassium chloride (KCl) stimulation was 0.67 土 
0.05 g. The initial tension of the tail artery strip should be greater or equal to 
0.5 g in order to ensure a satisfactory response upon stimulation of SME (Li, 
1989). 
C. Cardiovascular Effects of Dialyzed Samples of SME (Molecular Mass cutoff 
12000) in Spontaneously Hypertensive Rats (SHR) and Normotenslve Rats 
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I. Blood Pressure Effects 
Figure 18 shows the responses of the normotensive rats to DUL12000 and 
DLL12000. DUL12000 produced only slight hypotensive effect (p< 0.025， 
Fc功=3 3 4 , Fdi,=2.69) especially when compared with DLL12000. DLL12000 
induced significant changes in MAP (p<0.0005, Fe^=12.12, Fau=2.90). The 
pattern of changes in MAP by DLL12000 was very similar to that of SME. 
Furthermore, the hypotensive response of DLL12000 was compared between 
male SD rats and male SHR. The dose response curve in SHR appeared to shift 
to the left (Figure 19: p<0.005, Fe.i= 14.99, F,u=2.87 for male SD rats, 
p<0.0025, Fcai=7.43, F^=2.95 for male SHR). 
n . In vitro Arterial and Cardiac Effects 
The initial atrial rate of SD rats was 210 土 27 beat/min. The rates induced by 
； different doses of DLL12000 were statistically different (p< 0.025, F�.产4.71, 
I 
I Fdu=3.11). With doses from 2 to 200 mg/L, the greater was the dose of 
DLL12000, the greater was the chronotropic response. When the dose reached 
800 mg/L, atrial rates decreased sharply (Figure 20). The initial atrial tension 
was 0.28 土 0.09 g. DLL12000 did not induce significant changes (Figure 21). 
DLL12000 produced significant changes in the contractile force of isolated tail 
artery strips (p< 0.025, Fe.,=74.3, Fdi.=3.06). The contractile effect induced in 
male SHR tail artery was dose-dependent. The higher the concentration of 
DLL12000, the greater was the contractile force induced in tail artery (Figure 
22). 
The vasorelaxing effect of phentolamine ( an alpha adrenoceptor blocker) on 
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DLL12000 (3.4 g/L) stimulated artery strips was significantly different among 
different groups (p<0.0005, F�,产 19.92, and the curve was a dose-
dependent one. The higher the cumulative dose of phentolamine, the greater was 
the decrease in tension (Figure 23). The vasorelaxing effect of propranolol 
induced by DLL12000 was also dose-dependent. The higher the dose of 
propranolol, the greater was the decrease in tension. The tensions in different 
groups were statistically different from one another (Figure 24: p < 0.0005, 
Fcai=25.26, Fdi,=2.53). Moreover, the vasorelaxing effect of phentolamine was 
greater than that of propranolol. 
The inhibitory effect of phentolamine on DLL12000 induced contraction is shown 
in Figure 25, and the inhibitory effect of propranolol on DLL12000 induced 
contraction is shown in Figure 26. Both phentolamine and propranolol showed 
that when there was an increase in concentration of either blocker, there was a 
i 
decrease in tension developed by DLL12000 (3.4 g/L). The changes induced 
were statistically different (Figure 25: p<0.0005, F«a=24.19,尸彻=3.01; Figure 
26: p<0.0005, Fcai=29.35, ?彻=2.76). Comparing the results, the blocking 
effect of phentolamine was more effective than propranolol. 
D. Cardiovascular Effects of Dialyzed SME (DUL8000 and DLL8000) in 
Spontaneously Hypertensive Rats (SHR) and Normotensive Rats 
I. Blood Pressure Effects 
Both DUL8000 and DLL8000 exhibited hypotensive effects in different types 
of rats (Figures 27 and 28) with different degrees. DUL8000 produced 
significant changes in MAP in young male SD rats (p<0.025, Fc.,=3.94, 
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F彻=2.76)，in female SD rats (p<0.0005, Fe.,=36.7, Fdi.=2.8), male SD 
rats (p<0.0005, F�,丨=21.65, F彻=2.87) as well as female SHR (p<0.0005, 
17.74, Fdi.=2.87). Figure 27 demonstrates that the blood pressure 
changes induced by DUL8000 were also dose-dependent in male 
normotensive, female normotensive rats and female SHR. An increase in 
concentration of DUL8000 resulted in an increase in the depressor effect. 
However, the depressor response of DUL8000 was the highest in female 
SHR. The maximal decrease in MAP at 180 mg/kg was 128 土 9 mmHg in 
female SHR, 92 土 7 mmHg in male normotensive rats, 62 土 7 mmHg and 
24 土 6 mmHg in female normotensive rats and in young male normotensive 
rats respectively. 
SHR was bom with high blood pressure, its MAP was about 160 mmHg 
•i 
which was 40 mmHg higher than normotensive rats. This might account for 
I the greater decrease in MAP. The depressor effect was also greater in male 
I normotensive rats than in female rats, while the depressor effect in young 
！ • • male normotensive rats was the least. 
The hypotensive responses produced by DUL8000 were a bit different when 
compared with those of DLL8000. DLL8000 produced no significant 
changes in MAP in young male SD rats and male SD rats. DLL8000 
exhibited significant changes in MAP in female SD rats (p< 0.005, 
Fci=5.99, F彻=2.87) as well as in female SHR (pCO.Ol, Fe^=5.16, 
Fdu=2.87). The decrease in MAP induced by DLL 8000 was also the highest 
in female SHR. The maximal decrease, however, was only 46 土 10 mmHg 
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(Figure 28), while the maximum decreases in MAP were 25 土 4 mmHg in 
female normotensive rats, 16 士 7 mmHg in male normotensive rats, and 11 
土 8 mmHg in young male normotensive rats respectively. These results also 
suggested that the depressor response of both DUL8000 and DLLSOOO were 
strain-, sex- and age-dependent. 
When the hypotensive responses of DUL8000 and DLLSOOO were compared 
in the same group of rats in Figures 29，30, 31 and 32, the magnitude of the 
hypotensive effect of DUL8000 was greater than that of DLLSOOO. Besides, 
the depressor effect of DUL8000 was greater than that of DLLSOOO in 
different groups, such as in male normotensive rats (Figure 29), in female 
normotensive rats (Figure 30), in female SHR (Figure 31), and in young 
i 
male normotensive rats (Figure 32). These results suggested that perhaps 
more hypotensive active components might be present in the fraction 
DUL8000. 
n. In vitro Arterial and Cardiac Effects 
The responses of isolated right atria in different groups of rats are shown in 
Figures 33 and 34. Significant changes in atrial rate were demonstrated in 
young male SD rats treated with DUL8000 (pCO.Ol, Fe.,=4.84, Fdu=2.76), 
in female SD rats (p<0.0005, F,^=11.56, Fdu=2.87), in male SD rats 
(p<0.01, Fc.,=4.28, F彻=2.61) and in female SHR (p<0.005, Fc.,=5.95, 
Fdi,=3.06). The chronotropic effect of DUL8000 on isolated right atria in 
different groups of rats were basically dose-dependent. With doses from 3 
to 300 mg/L, the greater was the dose of DUL8000, the greater was the 
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chronotropic response. When this reached 3 g/L, atrial rate and tension 
plunged sharply (Figures 33). The initial atrial rates of normotensive male, 
female, young male and female SHR were 296 土 24，245 土 6, 333 土 40 
and 254 土 10 beat/min respectively. The initial atrial tension of normal 
male, female, young male and female SHR were 0.46 土 0.06, 0.62 土 0.12, 
0.43 士 0.08 and 0.43 土 0.03 g respectively. However, DUL8000 produced, 
with doses used, no significant difference in inotropic effects in female SD 
rats and in female SHR and young male SD rats except in female SD rats 
(p<0.025, Fe.,=4.03, F,u=2.87). 
The contractile effects of DUL8000 on tail arteries in different groups are 
shown in Figure 35. DUL8000 produced significant changes in contractile 
force of tail artery strips in male SD rats (p< 0.0005, 14.54, 
j 
F彻=3.10)，female SD rats (p<0.0005, Fe.,=34.25, Fd丨,=3，10) and female 
SHR (p<0.0005, Fca丨=28.15, F彻=2.95). When there was an increase in 
concentration of DUL8000, an increase in the contractile force was 
observed. Besides, the patterns of change in contractile force of DUL8000 
in different groups were very similar. 
DLLSOOO produced significant changes in atrial rate in young male SD rats 
(p<0.0005, Fcai=9.99, female SD rats (p<0.0005, F^.,=55.56, 
Fdu=2.87)’ male SD rats (p<0.0005, 17.70, Fdu=2.93) and female 
SHR (p< 0.0005, Fcd=36.51, Fdu=2.78). Besides, the chronotropic effects 
of DLLSOOO on isolated right atria in different groups of rats were also 
basically dose-dependent. Higher cumulative doses of DLLSOOO produced 
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greater chronotropic responses from 3 to 300 mg/L. When the concentration 
reached 3 g/L, atrial rate and tension plunged sharply (Figures 36). 
DLL8000 produced significant changes in atrial tension in male SD rats 
(p<0.05, Fcai二3.49, Fdi.=2.96) and young male SD rats (pCO.Ol, 
53’ F彻=2.87) but not in female SD rats and female SHR. For 
inotropic changes induced by DLL8000 in male SD rats and young male SD 
rats, they were dose-dependent (Figure 37). 
DLL8000 exhibited strongly significant increases in contractile forces of 
isolated artery strips in male SD rats (p< 0.0005, 14.54, ?彻=3.1)， 
female SHR (p<0.0005, Fe.,=28.15, F彻=2.95) and female SD rats 
(p<0.0005, F,^=34.25, ?彻=3.1). They are sigmoidal curves with the 
contractile force increases with increases in concentrations of DLL8000 
(Figure 38). Besides, the patterns of increase in contractile forces in different 
I 
groups were almost identical. 
For comparison, the chronotropic effect of both DUL8000 and DLL8000 in 
the same group of rats were shown in Figures 39, 40 and 41. The patterns 
of chronotropic effect were very similar in different groups, but the extent 
of chronotropic response of DLL8000 was greater than that of DUL8000. 
The inotropic effects of DUL8000 and DLL8000 in the same set of rats were 
also shown in Figures 42, 43 and 44 respectively. There were no significant 
differences in the responses between the two dialyzed SME fractions 
(DUL8000 and DLL8000) in all sets of rats. 
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The contractile effects of DUL8000 and DLLSOOO were also shown in 
Figures 45, 46 and 47. The magnitudes of contractile effect of two samples 
on tail arteries were very comparable. 
E. Acute Oral Effect of SME on Blood Pressure 
Three doses of DUL8000 or DLLSOOO, 4, 40 and 400 (mg/kg) did not diminish 
MAP significantly when compared with its own control respectively (Figure 48). 
F. Chronic Dietary Effect of SME on Blood Pressure, Total Free Serum 
Cholesterol and Triglyceride Levels 
The MAP of four groups (0, 4, 40 and 400 mg/kg of SME) were not statistically 
different from one another. The same applied to cholesterol levels as well as 
i 
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Figure la. A physiograph tracing showing the immediate response and succeeding 
hypotensive response of the male SD rats upon i.v. injection of SME. 
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Figure lb. Single-dose response curve on hypotensive effect of SME in male 
SD rats. Vertical bars represent SEM. Dosage was administered in 
mg dry weight per kg body weight. MAP before injection was 
131 土3 mmHg(n=10). 
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Figure 2. Cumulative-dose response curve on hypotensive effect of SME in 
male SD rats. Vertical bars indicate SEM. MAP before injection 
was 139±8 mmHg (n=5). 
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Figure 3. Hypotensive effect of SME in male SD rats. MAPs before and first 
and second injections were 128 土4 (n=20) and 111土6 mmHg 
(n=19). * denotes significant difference between the first and 
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Figure 4. Effect of autonomic ganglion transmission blockade on the 
hypotensive effect of SME in male SD rats. The initial MAP 
was 118土 12 mmHg (n=6). * denotes significant difference 
compared with the control (p<0.05). 
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Figure 5. Effect of alpha-adrenergic activity blockade on the hypotensive 
effect of SME in male SD rats. MAP before injection of SME was 
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Figure 6. Effect of beta-adrenergic activity blockade on the hypotensive effect 
of SME in male SD rats. MAP before injection of SME was 115 士4 
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Figure 7. Effect of cholinergic activity blockade on the hypotensive effect of 
SME in male SD rats. MAP before injection of SME was 104 土6 
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Figure 8. Effect of histaminergic activity blockade on the hypotensive effect of 
SME in male SD rats. MAP before injection of SME was 117 土4 
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Figure 10. Effect of phentolamine on hypotensive changes induced by SME in male SD 
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Figure 11. Effect of captopril infusion on MAP changes of SME in male SD rats. 
Initial MAP was 148土9 mmHg. * represents significant difference before 
and after infusions of captopril in different groups (p<0.05). 
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Figure 12. Effect of captopril infusion on action of SME in male SD rats. 
Vertical bars denote SEM (n=5). * represents significant 
difference before and after infusions of captopril in different 
groups (p<0.05). 
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Figure 13 and 14. Effect of SME infusion on urine and sodium excretion 
in water-loaded male SD rats. Vertical bars illustrate 
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Figure 15. Chronotropic effect of SME on isolated right atria of male SD rats. Initial 
atrial beat was 324士 18 beat/min. Vertical bars illustrate SEM (n=9). 
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Figure 16. Inotropic effect of SME on isolated right atria of male SD rats. Initial 
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Figure 17. Contractile effect of SME on male SD rat tail artery strips. The tension of 
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Figure 18. Cumulative-dose response curves of DUL12000 (MW 
> 12000), DLL12000 (MW< 12000), and SME in male SD 
rats. MAP before injection were 114士8, 111土9 and 134土3 
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Figure 19. Dose response curves of DLL12000 (MW< 12000) in male SD rats and 
male SHR. MAP before injection of extracts were 138 士3 mmHg and 
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Figure 20. Chronotropic effect of DLL12000 (MW< 12000) on isolated right atria of 
male SD rats. Vertical bars illustrate SEM (n=8). 
87 
0 . 6 0 - T 
. A 
3 0.45 - f \ 
I \ T T 
S \ 丁 
-3 
is 0.30 xt 丄 
0.15 -
J I I I I _ 
0 500 1000 1500 2000 
DLL12000 (mg/L) 
Figure 21. Inotropic effect of DLL12000 (MW< 12000) on isolated right atria of male 
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Figure 22. Contractile effect of DLL12000 (MW < 12000) on male SD rat artery strips. 
The tension of helical strips stimulated by KCl was 1.15 ±0.05 g prepared 
for DLL12000 testing. Vertical bars denote SEM (n=8). 
89 
• 
0.6 _ J 
T - \ 




. I I I 1 
10-2 10-1 10� IqI 10^ 
Log Concentration of Phentolamine (mg/L) 
Figure 23. Vasorelaxing effect of phentolamine on male SD rat tail artery strips 
preconstricted by DLL12000 (3.4 g/L). Tension preconstricted by 60 mM 
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Figure 24. Vasorelaxing effect of propranolol on male SD rat tail artery strips induced 
by DLL12000 (3.4 g/L). Tension preconstricted by 60 mM KCl was 
0.72 土0.05 g prepared for testing. Vertical bars denote SEM (n=7). 
91 
I 0.6 _ \ 
§ \ 
！ \l ；D “ t \ a> \ 
I A 
t 0.3 一 \ 
1 \ m \ 
0.0 I ‘ ‘ ^ ^ 
10-2 10-1 1 0 � 10i 10^ 
Log Concentration of Phentolamine (mg /L) 
Figure 25. Inhibitory effect of phentolamine on contractile tension of male SD rat tail 
artery strips induced by DLL12000 (MW< 12000, 3.4 g/L). Vertical bars 
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Figure 26. Inhibitory effect of propranolol on contractile response of male SD rat tail 
artery strips preconstricted by DLL12000 (MW< 12000, 3.4 g/L). Vertical 
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Figure 27. The hypotensive effects of DUL8000 (MW between 8000 to 12000) in 
young male, male, female SD rats, and female SHR. MAP before injection 
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Figure 28. Hypotensive effects of DLL8000 (MW below 8000). Vertical bars represent 
SEM. MAP before injections in young male, male, female SD rats and 
female SHR were 96土5(n=6), 142土9(n=6), 117土ll(n=5)，and 
128 土9(n=6) mmHg. 
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I rigure 29. The hypotensive effects of DUL8000 and DLL8000 in male SD rats. MAP before 
administration of SME preparations were 145 土 5 (n=5), and 142 士 9 (n=6) mmHg 
respectively. Vertical bars denote SEM. 
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Figure 30. The hypotensive effects of DUL8000 and DLL8000 in female SD rats. MAP before 
administration of SME preparations were 107土9 (n=6), and 117 土 11 (n=5) mmHg 
respectively. Vertical bars denote SEM. 
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administration of extracts were 174土4 (n=5), and 128土9 (n=6) mmHg respectively. 
Vertical bars denote SEM. 
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Figure 32. The hypotensive effects of DUL8000 and DLL8000 in young male SD rats. MAP before 
administration were 110土3 (n=6), and 96士5 (n=6) mmHg respectively. Vertical bars 
denote SEM. 
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Figure 33. The chronotropic effects of DUL8000 (MW between 8000 to 12000) on 
isolated right atria in male, female, young male SD rats and female SHR. 
Vertical bars represent SEM (n=6). 
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Figure 34. The inotropic effects of DUL8000 (MW between 8000 and 12000) on 
isolated right atria in female, male SD rats, female SHR and young male 
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Figure 35. Contractile effect of DUL8000 on tail artery strips. The tension 
preconstricted by KCl on helical strips were 0.61 土0.06 (6 SD), 0.61 土0.04 
(9 SD), and 0.56±0.02 (9 SHR ) g. 
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Figure 36. The chronotropic effects of DLLSOOO (MW below 8000) on isolated right 
atria in young male, female, male SD rats and female SHR. Vertical bars 
represent SEM (n=6). 
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Figure 37. The inotropic effects of DLL8000 (MW below 8000) on isolated right atria 
in male, female SD rats, female SHR and young male SD rats. Vertical bars 
illustrate SEM (n=6). 
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Figure 38. Contractile effects of DLLSOOO on tail artery strips. The tensions of KCl-
preconstricted helical strips were 0.61 土0.06(<J SD), 0.61 土0.04(9 SD), and 
0.56士0.02(9 SHR) g. 
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Figures 39, 40 and 41. The chronotropic effects of dialyzed samples on isolated right 
atria of different groups. Vertical bars denote SEM (n=6). 
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Figure 42. The inotropic effects of DUL8000 (initial atrial tension: 0.62土0.116 g) and 
DLL8000 (initial atrial tension: 0.54士0.098 g) on isolated right atria of 
female SD rats. Vertical bars denote SEM (n=6). 
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Figure 43. The inotropic effects of DLL8000 (initial atrial tension: 0.56士0.09 g) and 
DUL8000 (initial atrial tension: 0.46土0.06 g) on isolated right atria of 
male SD rats. Vertical bars denote SEM (n=6). 
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Figure 44. The inotropic effects of DLL8000 (initial atrial tension: 0.54士0.01 g) and 
DUL8000 (initial atrial tension: 0.425 +0.031 g) on isolated right atria of 
female SHR. Vertical bars denote SEM (n=6). 
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Figure 45. The contractile effects of DLLSOOO and DUL8000 on tail artery strips of 
male SD rats. The tension stimulated by KCl was 0.61 ±0.06 g for testing. 
Vertical bars denote SEM (n=6). 
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Figure 46. The contractile effects of DLLSOOO and DUL8000 on tail artery strips of 
female SD rats. The tension stimulated by KCl was 0.61 土0.04 g for 
testing. Vertical bars denote SEM (n=6). 
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Figure 47. The contractile effects of DLL8000 and DUL8000 on tail artery strips of female SHR. The t nsion stimulated by KCl was 0.56土0.02 g for testing. Verti al b rs deno  SEM (n=6). 
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Figure 48. Acute oral effects of DUL8000 and DLL8000 on MAP in male SD rats. 
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The study was complicated with the finding in the beginning because boiled SME did 
not kill rats up to a concentration of 800 mg/kg, while the unboiled SME caused 
death of rats with as little as 10 mg/kg. This was probably due to the presence of 
volvatoxin (Table 2). Lin (1973) reported that there was a cardiotoxic protein in straw 
mushrooms. The toxic protein was named as volvatoxin which is composed of two 
major components, Al and A2 with molecular weights of 50,000 and 24,000. Rats 
could be killed due to ventricular systolic arrest with as little as 2 to 5 mg crude dry 
weight per kg body weight through intraperitoneal injection. The toxicity of 
volvatoxin could be eliminated by heating at 100°C for 20 minutes. 
Since the research interest was to study straw mushrooms as a possible health food, 
and straw mushrooms are normally taken properly cooked. Only boiled SME was 
used for further experiments. 
A. The Hypotensive Effect of SME 
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I The present study demonstrated a hypotensive effect in the aqueous extract of 
i 
straw mushrooms in both the "elongation" and "egg" stages (Appendix VII) in 
rats upon intravenous injections (Figures lb and 2). Upon intravenous injection 
of SME, a transient decrease in MAP was observed (Figure la). There followed 
by an increase in blood pressure and then a succeeding and longer hypotensive 
response which was measured and recorded as the hypotensive response of SME. 
The response of SME was typically dose dependent with an ED50 value of 25 mg 
dry weight per kg body weight. The maximum response of male rats was a 
decrease of about 56 土 10 mmHg when given single doses, and a greater 
decrease of 75 土 9 mmHg when given cumulative doses (Figures lb and 2). 
Tachyphylaxis was not observed (Figure 3) unless the concentration of SME 
reached 120 mg dry weight equivalent per kg body weight. The present findings 
on the hypotensive effect of V. volvacea were therefore in agreement with those 
in some edible mushrooms, such as Agaricus bisporus, Pleurotus ostreatus and 
Lentinus edodes. Agaricus bisporus has especially been used clinically to lower 
blood pressure in China (Huang, 1987). Chronic ingestion of Pleurotus sajur-caju 
has an excellent effect on controlling blood pressure especially in hypertensive 
patients. Tarn et al (1986) showed that an aqueous extract of Pleurotus sajor-
caju has a hypotensive effect in rats. A typical dose of 25 mg/kg of the extract 
decreased the mean arterial pressure from 110 mmHg to 70 mmHg. Kabir and 
Kimura (1989) reported that Ganoderma lucidum was a folk medicine which had 
been used to treat hypertension. 
B. The Hypotensive Action of SME: Mechanism of Action 
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Based on the results from the pharmacological antagonist studies, the hypotensive 
response of SME was neither mediated via B-adrenoceptor receptors (Figure 6) 
nor muscarinic receptors (Figure 7) nor the renin-angiotensin system (Figures 11 
and 12). Application of the appropriate specific blockers did not affect the effects 
of SME. 
Captopril is an enzyme inhibitor which is employed to lower the blood pressure 
of hypertensive patients. The hypotensive effect of SME was unexpectedly 
abolished after the infusion of captopril. Theoretically, captopril enhances the 
hypotensive effect and prolong the duration of 75% recovery if it in acting on 
angiotensin. However, the results were opposite (Figures 11 and 12) to what 
were expected. Thus, no explanation could be offered. 
Figure 4 demonstrates that the pretreatment with autonomic ganglionic blocker 
(hexamethonium, 10 mg/kg) could block SME-induced hypotension in 
anesthetized normotensive rats. The blocking effect of hexamethonium on the 
MAP induced by SME was a dose-dependent (Figure 9). This indicated that the 
depressor effect of SME might be via the autonomic nervous system. 
With ganglionic suppression, or modulation, the depressor effect of SME via the 
of-adrenergic system seen in the present study (Figure 5) could be understandable. 
With pretreatment of normotensive rats with pyrilamine and cimetidine (Hj and 
H2 antagonists) simultaneously, MAP was reduced significantly. This indicated 
that the hypotensive action of SME might be mediated through histaminergic 
activity (Figure 8, e.g. release of histamine). This also indicated that there was 
1 1 1 
more than one active ingredient. However, substances which decrease blood 
pressure through the histaminergic action are not chosen as antihypertensive 
drugs for two reasons. Firstly, the depressor effect can be corrected once a 
substance can block both H, and Hj receptors simultaneously especially H, 
receptors which are the predominant vascular histamine receptors (Sham, 1983). 
If the substance can block either one of them, the depressor effect is not 
satisfactory. Secondly, among the 500 clinically used antihypertensive substances, 
there are none which decrease the blood pressure through the histaminergic 
activity. 
Blood pressure changes might be related to the amount of urine and amount of 
sodium excreted by the kidney. For instance, increase in arterial pressure will 
increase urinary volume and sodium output. With reference to Figures 13, three 
different doses of SME (0.3, 1 and 3 mg/min respectively) encouraged urinary 
excretion in rats. Though the increase in amount of urine was not statistically 
significant, its trend was still observed. The relation between the total amount of 
sodium excreted in rats and SME infused was however not obvious (Figure 14). 
In summary, SME acted on autonomic system, of-adrenergic system, 
histaminergic system and perhaps urinary excretion as well. 
In the in-vitro study, SME showed positive inotropic and chronotropic effects on 
the isolated right atrium, both of which were dose-related (Figures 15 and 16). 
The results suggested that SME contained substance(s) which act on the B-
adrenoceptors and serve as a fi-adrenoceptor agonist. This suggestion is based on 
two reasons. Firstly, the B-adrenoceptors are mainly found in the heart (Rang, 
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1987). Secondly, fi-adrenoceptor agonist acts almost entirely on 15-receptors 
resulting in increases in rate and force of the heart (Bell, 1980). However, it 
would be a much better proof if tests were made with propranolol. 
On the other hand, data from the tail artery study showed that SME was not a 
vasorelaxatory substance. It might contain a mixture of substances and some of 
them are vasoconstrictory (Figure 17). The preconstrictor employed in the study 
was potassium chloride which was used to verify the flexibility of the vessels 
isolated (Sham, 1983). Data obtained from Figure 17 could be explained as 
previously in that SME might contain some substances which acted on a,-
receptors and serve as an a丨-adrenoceptor agonist stimulating vasoconstriction in 
tail arteries. 
In summary, SME was a mixture of substances some of which acted on a-
adrenoceptors and B-adrenoceptors, the effects of these substances could not 
account for a direct hypotensive action of SME. The resulting and succeeding 
hypotensive response might be due to several attributes. Firstly, it might be a 
counter-action after the increase in MAP, induced by some substances which act 
on of-adrenergic receptors. Secondly, there were substances which acted 
as/promoted local kinin-like substances thereby decreasing the blood pressure via 
vasodilation. Thirdly, the combination of the actions of histaminergic activity 
(i.e. promoting histamine release) and urinary excretion might contribute to the 
hypotensive response of SME. 
C. The Cardiovascular Active Fractions in SME 
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Since SME was a crude aqueous extract, it probably consisted of a mixture of 
substances which acted on different systems. It was important to purify SME in 
order to isolate the active substances. In the present study, dialysis was used 
which separates a mixture of substances according to their differences in 
molecular mass. After the first dialysis, two samples were produced, one was 
DUL 12000 (Molecular weight > 12000), the other was DLL12000 (Molecular 
weight < 12000). 
Data obtained from Figure 18 demonstrate that most of the hypotensive active 
substances were present in sample DLL12000, indicating that the active 
substances were with molecular weight less than 12000 dalton. The maximum 
decrease in MAP was 64 土 8 mmHg for DLL12000, but was only 5 士 1 mmHg 
for DUL12000. The hypotensive response of DLL12000 was dose-related, it was 
a sigmoid-shaped curve with ED50 of 25 mg dry weight per kg body weight. With 
reference to the hypotensive effect of SME in Figure 2, the maximal decrease in 
MAP produced was 75 士 9 mmHg which was a little bit higher than that 
produced by DLL12000, but the data obtained was acceptable for there might be 
some loss during the purification step. 
In the in-vitro study, DLL12000 produced positive chronotropic and inotropic 
responses in isolated atria. The responses were dose-dependent (Figures 20 and 
21). The contractile effect of DLL12000 in the male SHR tail artery was dose-
dependent. The higher the concentration of DLL12000, the greater was the 
contractile force in the helical tail artery strip (Figure 22). Furthermore, the 
contractile response of the artery strips was antagonistized by a-adrenoceptor 
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blocker (phentolamine), and B-adrenoceptor blocker (propranolol) (Figures 23 and 
24). The higher the concentration of the blocker, the greater was the decrease in 
the tension of the artery strip induced by DLL12000 (3 g/L). Data thus suggested 
that the vasoconstrictory effect of DLL12000 can be relaxed with these 
adrenergic blockers. This, in turn, indicated that the vasoconstrictory effect of 
DLL12000 was mediated via of-receptor stimulation. However, the role of 
propranolol played was not known. It should be noted that a much higher dose 
of propranolol (lOx) was required to produce a similar antagonistic effect 
compared with phentolamine. This mode of action of DLL12000 on the vascular 
smooth muscle is also supported by the finding that in the presence of 
phentolamine which blocks the a-adrenoceptor, the tension developed by 
DLL12000 was smaller (Figure 25) when the concentration of the blocker was 
higher. Similar response was observed in case of propranolol (Figure 26). In 
summary, DLL12000 contains active substances as those in SME. 
DLL12000 sample was further dialyzed in the present study into two fractions 
using tubing with a cutoff point of 8000. One was DUL 8000 (Molecular weight 
between 8000 and 12000), which was retained inside the tubing and the other was 
DLL8000 (Molecular weight below 8000) which was passed into distilled water. 
The results demonstrated both DUL8000 and DLL8000 were different in their 
effect on the cardiovascular activity in different strains of rats, at different ages 
and in both sexes (see below). 
D. The Cardiovascular Effect of DUL8000 and DLL8000 in Rats with Reference 
to Age, Sex and Strains 
115 
Results of the present study showed that in the male SD rats, both DUL8000 and 
DLL8000 produced dose related hypotensive responses (Figures 27 and 28). At 
100 mg/kg, DULSOOO decreased the MAP by 80 mmHg in these rats while 
DLL8000 decreased it by 10 mmHg. This strongly indicated a good separation 
of the hypotensive substances in DLL12000. With the similar dose of 100 mg/kg, 
DLL12000 produced only a decrease in MAP in the male-rat of about 60 mmHg 
(Figure 19). 
Furthermore, both DULSOOO and DLL8000 were stimulatory to the isolated atria 
of male SD rats. DLL8000 was however more effective than DULSOOO, and 
yielded greater chronotropic and inotropic responses. These findings suggested 
a separation of the cardioactive substances in addition to that of the hypotensive 
component with a molecular cutoff of 8000 dalton for these substances. In 
contrast, there was no difference in the maximal contractile response of the tail 
artery preparation from male SD rats to either DULSOOO or DLLSOOO. 
In summary, these data showed the presence, and separation, of the hypotensive 
and cardiac active substances in SME. 
J 
Among the four groups (such as young male SD, male SD, female SD and 
female SHR), the hypotensive response of female SHR to DUL8000/DLL8000 
was obvious (Figure 31). This was also observed previously with DLL12000 in 
the male SHR (Figure 19). This might be due to the higher basal blood pressure. 
MAP of SHR was about 40 mmHg higher than that of SD rats. Thus, it allowed 
a greater extent in the decrease in MAP. In SD rats, the depressor effect was 
116 
greater in male normotensive rats than in female normotensive rats, while the 
depressor effect in young male normotensive rats was the lowest. These results 
suggested that the depressor effect of DUL8000 was strain- dependent, being 
more in SHR than 
normotensive rats. Besides this, the decrease in blood pressure in response to 
DUL8000 was also sex-dependent and age-dependent (Figure 27). 
It should be noted that the depressor effect of DUL8000 was greater than that of 
DLLSOOO in different groups, such as in male normotensive rats (Figure 29), in 
female normotensive rats (Figure 30), in female SHR (Figure 31), and in young 
male normotensive rats (Figure 32). These results suggest therefore that the 
hypotensive active substances are more abundant in DUL8000 than in DLLSOOO. 
For further purification of hypotensive active components, DUL8000 should be 
used. 
Data from the in-vitro studies showed as expected that DUL8000 and DLLSOOO 
produced positive chronotropic and inotropic effects on isolated atria as well as 
being vasoconstrictory in rat artery strips of male normotensive rats, female 
normotensive rats, young male normotensive rats and female SHR. The 
chronotropic and inotropic effects of DLLSOOO were however greater than those 
of DUL8000 in male normotensive rats, female normotensive rats as well as in 
female SHR (Figures 39,40, and 41). These data suggested the presence of more 
cardioactive substances in DLLSOOO than in DUL8000 which stimulate atrial beat 
and atrial tension. Concerning the vasoactive properties, the maximum tension 
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developed by DUL8000 at 3 g/L in male normotensive rats was 0.64 土 0.08 g 
and that of DLL8000 was 0.64 土 0.05 g, these data suggested that both samples 
contained relatively similar amount of vasoconstrictory substances or different 
amount/nature but being equipotent. The mode of vasoconstrictory action of both 
DUL8000 and DLL8000 might be similar to that of serotonin (Appendix VIII), 
in view of the findings that ketanserin (a serotonin blocker) could block the 
constrictory action of both fractions. 
E. The Oral Effect of SME on Blood Pressure and on Serum Cholesterol and 
Triglyceride Levels 
The results of the present study showed that three doses of DUL8000 or 
DLL8000, 4, 40, and 400 mg/kg did not diminish MAP significantly within 
thirty minutes (Figure 48), when SME was given orally. It implied that the 
hypotensive effect was only demonstrated when given through the intravenous 
route. These results suggest that straw mushrooms cannot be used at this stage 
as an oral active antihypertensive substance. 
The findings obtained from this acute study received support from those of the 
chronic study. The blood pressure, total serum cholesterol as well as total serum 
triglyceride levels after eight weeks chronic dietary feeding of SME in male 
normotensive rats showed no difference (Figure 49). The daily dose went up to 
as high as 400 mg/kg. 
However, these results could not prove that straw mushrooms were not able to 
lower blood pressure, cholesterol and triglyceride levels when taken orally for 
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a period of time, (say eight weeks as in the present study) for several reasons. 
Firstly, normotensive rats were used, whose blood pressures were normal. Straw 
mushrooms may perhaps only function in patients or rats with high blood 
pressure (i.e. hypertensive animals). Should SHR be used for the experiment, the 
results may be different. 
I 
I Secondly, MAP was measured eight weeks after the experiment. The changes in 
i 
MAP were not observed during the feeding period. In other words, SME might 
be able to lower blood pressure during the feeding period, but then the blood 
pressure was restored back to normal levels. Kabir and Kimura (1989) observed 
that MAP was lowered 35 days after the start of feeding with mannentake in rats. 
However, MAP increased gradually in the last 15 days. Thus, to understand the 
hypotensive effect of straw mushrooms, one might have to check MAP 
periodically. 
Thirdly, the cholesterol level of the rats was normal, the ability to further 
decrease it with SME at the present feeding regime might not be observed. Thus, 
Setsuko et al (1974) fed the rats with extra cholesterol and observed the ability 
of the extract of shiitake mushroom in lowering the cholesterol level. 
Finally, only aqueous extract of straw mushrooms were tested. The hypotensive 
active substances which were soluble in organic solvent were not studied. It was 
reported by Kyoko (1988) that Grifola frondosa mushroom extract soluble in 
ether and suspended in 33% propylene glycol decreased MAP by 70 mmHg in 
intact animals. 
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Although the accumulation of information on the effects of straw mushrooms may 
not excite everyone, some enthusiasts persist and their endeavors may increase 
the amount of data until it reaches a critical mass. To achieve that state, more 
research is needed to discover, verify and apply the medicinal effects of higher 
fungi. 
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SUMMARY 
(1). Straw mushroom extract (SME) demonstrated a hypotensive effect in rats upon 
intravenous injections. Tachyphylaxis was not observed unless the 
concentration of SME reached 120 mg dry weight equivalent per kg body 
weight. 
(2). From the pharmacological antagonist studies, the hypotensive effect of SME 
was not mediated via B-adrenoceptor receptors nor muscarinic receptors nor 
renin-angiotensin system. On the contrary, the depressor effect of SME may 
be via the autonomic system, a-adrenergic system and/or histaminergic 
system. 
(3). SME increased urine excretion, but not sodium excretion. 
(4). SME showed positive inotropic and chronotropic effects on the isolated right 
atrium, both of which were dose-related. Data from tail artery study showed 
that SME was a vasoconstrictor. 
(5). The results from the in-vitro studies suggested that SME were composed of 
substance(s) which was (were) cardioactive, probably acting via on the B-
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adrenoceptors, and produced positive chronotropic and inotropic effects. 
Furthermore, SME also contained some vasoactive substance(s) which had 
similar properties of a-adrenoceptor agonist which produced vasoconstriction 
(6). SME was purified by dialysis. 
(7). Based on the blood pressure changes and the in vitro effects on the atria and 
tail artery helical strip, the cardiovascular active substances found were mostly 
in a dialyzed sample with molecular weight less than 12000 (i.e. partially 
purified samples DLL12000, DUL8000 and DLL8000). However, the nature 
of these substances was unknown. 
(8) The cardiovascular effects of partially purified samples of SME in rats were 
strain dependent, sex dependent, and age dependent. 
(9). Chronic dietary effects of SME had been tested for eight weeks in male 
normotensive rats. These were given as high as 400 mg/kg SME/day but they 
showed no difference in blood pressure, total serum cholesterol and total 
triglyceride levels when compared with the control group at the end of the 
feeding period. The straw mushroom did not show hypotensive nor 
hypolipidemic effects via oral route. 
(10). Acute feeding through intubation of dialyzed sample (molecular mass between 
8000 and 12000 i.e. DUL8000) 4, 40, and 400 (mg/kg) did not diminish the 
mean arterial pressure significantly within thirty minutes. The straw mushroom 
cannot be used at this stage (as high as 400，purified, extract mg/kg) as an oral 
antihypertensive substance. 
(11). The detailed mode of action of hypotensive effect of straw mushrooms was 




I in order to produce pure antihypertensive drug for clinical uses. Results from 
i 
I 
subsequent/further experiments, indicated that: 
a. The hypotensive effect was probably mediated via serotonin-like 
substances(s) in view of i) the similarity in the hypotensive response and 
ii) the inhibitory effect of serotonin blocker on the contractile response to 
( DUL8000 and DLL8000. 
b. The active hypotensive components were probably not peptide in nature in 
view of trypsin-digestion of DUL8000 and DLL8000 produced no 
differences in the hypotensive response in rats. 
c. DUL8000 could be separated into 9 fractions with a sphaedex column, 2 
of these produced significant decreases in MAP but were vasoconstrictory, 
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A simplified schema showing primary pathways for short-term regulation of 
arterial blood pressure 
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Source: Smith, J. J. and J. P. Kampine (1990) Circulatory Physiology, ed. p. 
163，Williams and Wilkins, Baltimore. 
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Appendix VIII 
The renin-angiotensin system and arterial blood pressure regulation. 
Decreased Blood Flow 
increased blood flow \ 
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Source: Strand, F. L. (1978) Physiology: A Regulatory Systems Approach, p.221, 
MacMillan Publishing Co., Inc., New York. 
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Appendix VIII 
Renal-body fluid mechanism for long-term regulation of arterial blood pressure 
O © ® 
Arterial pressure > Renal output of water > Extracellular 
T ~ ~ X and electrolytes p> fluid volume 
I ® 
Total peripheral ® 
resistance Net intake of 
I ；K water and 
I electrolytes 
I (Local vascular 
I regulation ) 
( p i 丨 厂 c i r c ^ u l a t � I ” � 
Venous return and ^ Blood 
Cardiac output 二 二 ^ ^ volume 
pressure 
As indicated in appendix IV，an increase in arterial pressure, Q，causes increased 
fluid out^t through the kidneys, a reduction in extra-cellular fluid volume, (?), blood 
volume,©and venous return,@. The subsequent decrease in cardiac output will act 
to reduce the arterial pressure. 
Source: Smith, J. J. and J. P. Kampine (1990) Circulatory Physiology, ed. p. 
179，Williams and Wilkins, Baltimore. 
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Appendix V 
Classification of drugs 
V 
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Categorization of antihypertensive drugs. Each column represents a class 
of antihypertensive drugs. The height of each column represents the total 
number of drugs assigned to each class. Within each class there is a 
subclassification to define the proposed mechanisms and/or sites of action. 
A total of 21 types within the major classes are decoded in the table. 
Source: Kaplan, H. R.，M. J. Ryan, R. M. Singer, D. M. Cohen, and R. M. 




Different stages in the development of straw mushrooms 
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Different stages in the development of straw mushroom. The biggest one 
at the left is the "mature" fruiting body. The second from the left, showing 
the volva which has been disconnected from the pileus by the rapid 
elongation of the stipe, is the "elongation" stage. The next two are "egg" 
stages showing that the universal veils have been ruptured. The rest are 
"button"，"tinybutton", and "pinhead" stages, consecutively. 
Source: Chang, S. T. and P. G. Miles (1986) Edible Mushrooms and Their 
Cultivation, p.226, CRC Press, Inc. Boca Raton, Florida. 
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Appendix VII 
The hypotensive effects of SME at "elongation" and "egg" stages 
A. Introduction: 
The development of straw mushrooms goes through different developmental 
stages, from "pinhead" to "mature" stages (Appendix VI). Some active 
components may exist in certain parts of the plant, or in certain stages of the 
plant. In this experiment, we wanted to verify that if the hypotensive active 
components of SME exist only in the "egg" stage, or also exist other 
developmental stages, such as the "elongation" stage. 
B. Materials and methods: 
Male SD rats weighing 300 to 350 g provided by the Animal House of University 
of Alberta were prepared for blood pressure measurement. SME of "egg" and 
"elongation" stages were prepared. Cumulative doses of SME were tested (2.5 
mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg and 80 mg/kg), starting with 
the smallest dose. 
C. Results and discussion: 
SME of the "elongation" stage induced significant changes in MAP (p< 0.0005, 
Fcai=16.93, Fdi,=2.45). The nature in these changes of MAP was a hypotensive 
one in the "elongation” stage or the "egg" stage when given i.v. in SD rats. The 
maximal decreases in MAP using SME of 80 mg/kg were 69 土 8 and 75 ± 9 
mmHg respectively (Figure App VII 1). Thus, it might be concluded that the 
hypotensive active substances were found in both stages of straw mushrooms. 
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Figure App VII 1. Cumulative-dpse response curves on hypotensive effect of 
SME in "egg" and "elongation" stages in male SD rats. 
MAPS before injection were 139 土 8 (n=5) and 124 士 6 
(n=6) mm Hg respectively. 
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Appendix VIII 
The inhibitory effect of ketanserine (serotonin blocker) on tension 
induced by DUL8000 or DLL8000 
A: Introduction: 
Close examination on the pattern of MAP changes induced by SME revealed that 
it was similar to that induced by serotonin (Zwieten, 1987). This experiment was 
therefore to find out whether DUL8000 or DLL8000 might contain some 
serotonin-like substances or not, with the use of a serotonin blocker. 
B. Materials and methods: 
Male SD rat tail artery strips were prepared. A small dose of ketanserine (10"^  
M), provided by the Department of Physiology, University of Alberta, was 
added. This was followed by DUL8000 or DLL8000 (200 mg/L) within 10 
seconds. The tension developed was measured. The tissue was rinsed with K-H 
solution for several times, and equilibrated for 10 minutes before application of 
a higher dose of ketanserine (10'^  to 10"^  M). 
C. Results and discussion: 
Katanserine produced an inhibitory effect on the tension induced by DUL8000 
(p<0.0005, Feai=16.64> Furthermore, it was negatively dose related 
(Figure App VIII1). The higher was the dose of ketanserine, the smaller was the 
contractile response developed. This was also seen using DLLSOOO (p< 0.0005, 
Fe.,=10.20, Fdu=3.6 as shown in Figure App VIII 2). Thus, it might be 
concluded that the vasoconstrictory effect of DUL8000 or DLLSOOO was similar 
to serotonin since ketanserine, a serotonin blocker, was able to block the 
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contractile effect induced by DUL8000/DLL8000. Serotonin was reportedly 
released into blood circulation during platelet aggregation. It was a local 
vasoconstrictor and acted as a vascular tone regulator. It had been reported that 
when serotonin was administered intravenously in intact animals, a triphasic 
response would be evoked in changes of blood pressure. There was an initial 
depressor effect, followed by a pressor response and the third phase of the blood 
pressure response was hypotensive again (Zwieten, 1987). This triphasic response 
curve was also observed when SME was injected intravenously in intact animals 
in the present study. Thus, the mechanism of hypotensive effect of SME might 
be similar to serotonin. 
It must be noted that the amount of serotonin blocker required to block the 
contractile response of DUL8000/DLL8000 was very minute compared with that 
required by a- or B-adrenergic blockers (Figures 25 and 26). This underscored 
the sensitivity of the smooth muscle in the tail artery strips to serotonin-like 
substances. Thus, it might be concluded that DULSOOO and DLLSOOO contained 
serotonin-like substances other than substances which bind to a- or B-receptors, 
or indeed serotonin-like substances might interact with these receptors. 
I 
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Figure App VIII 1. Inhibitory effect of ketanserin on tension of male SD rat 
tail artery strips induced by DUL8000 (MW between 
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Figure App VIII 2. Inhibitory effect of ketanserine on tension of male SD rat 
tail artery strips induced by DLLSOOO (MW below 8000). 
Vertical bars denote SEM (n=5). 
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Appendix VIII 
To study the hypotensive effects of trypsin-treated DUL8000/DLL8000 
A. Introduction: 
In the present study, the protein nature of DUL8000 or DLLSOOO was tested by 
comparing the hypotensive responses of trypsin-treated DULSOOO/DLLSOOO and 
untreated DUL8000/DLL8000 in SD rats. 
B. Materials and methods: 
DUL8000 or DLLSOOO was dissolved in 1 ml of buffer (50 mM ammonium 
bicarbonate, pH 7.8) containing trypsin (weight ratio of trypsin to tested sample 
was 1 to 50). The mixture was incubated at 37°C for 18 hours. These samples 
were heated to 96°C for 5 minutes before freeze dry. There were: one contained 
DUL8000/DLL8000, trypsin, and buffer, the second one served as the control 
containing DUL8000/DLL8000 and buffer only. Then, the control samples 
included: 1) trypsin only, 2) buffer only. All these samples and controls in 
different doses (0.5 mg/kg, 5 mg/kg and 20 mg/kg) were tested for their effects 
in MAP. Male SD rats weighing around 350 g were prepared for blood pressure 
measurement. 
C. Results and discussion: 
Samples consisting of trypsin and/or buffer only did not produce any MAP 
changes. Untreated DUL8000 produced changes in MAP (p<0.01, Fcai=8.12, 
Fjj,=4.10) and trypsin-treated DUL8000 also produced changes in MAP 
(p< 0.0005, F,^=17.16, Fdi.=3.98). Untreated DLLSOOO produced significant 
changes in MAP (p<0.005, Fe.,= 11.13, ?彻=3,68), trypsin-treated DLLSOOO 
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produced changes in MAP (p<0.001, Fe.,=8.12, ?彻=4.10). The hypotensive 
response patterns of untreated DUL8000/DLL8000 and trypsin-treated 
DUL8000/DLL8000 were similar (Figures App IX 1 and 2). This implied that the 
hypotensive activity of DUL8000/DLL8000 was not affected by trypsin treatment. 
It might be concluded that the substance(s) which accounted for the hypotensive 
response in DUL8000/DLL8000 was probably not protein in nature. 
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Figure App IX 1. The hypotensive effects of trypsin-treated and untreated 
DUL8000 in male SD rats. Vertical bars represent SEM 
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Figure App IX 2. The hypotensive effects of trypsin-treated and untreated 
DLL8000 in male SD rats. Vertical bars represent SEM 





The further purification of cardiovascular active substances in DULSOOO 
A. Introduction: 
In view of data obtained in Figures 29 to 32 which indicated that DULSOOO 
probably contained the active hypotensive substance(s) in SME, the present study 
attempted to further purify the substance(s). 
B. Materials and methods: 
A p-6 column was prepared and put in a cold room. About 0.2 g of DULSOOO 
was dissolved in ammonium acetate buffer and introduced into the column. 
Fractions eluted out depending on the molecular weight of the substances were 
collected at 20-minute intervals. A typical run would take 36 hours. 
Male SD rats were prepared for blood pressure measurement. Effects of different 
fractions on MAP in these rats were checked at a concentration of 20 mg/kg. 
Isolated artery strips were prepared for tension measurement. A single dose (300 
mg/L) of different fractions of DULSOOO were tested. Several wash with K-H 
solution were necessary between tests of different fractions of DULSOOO. 
Relaxatory effect of different fractions from DULSOOO was also studied. In this 
case, isolated tail artery strips were preconstricted with 60 mM potassium 
chloride, once the tension developed was steady, a dose (300 mg/L) of different 
fractions of DULSOOO was added. The change of tension, if any, was noted. 
D. Results and discussion: 
The profile of elution pattern was shown in Figure App X 1. Based on the 
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position of the 'peaks', all volume eluted were divided into 9 fractions (A to H) 
and void. These were lyophilized and reconstituted with saline for tests. Fractions 
C, and F of DUL8000 were hypotensive, especially C which showed a 31 ± 8 
mmHg decrease in MAP at 20 mg/kg i.v. administration (Figure App X 2). 
Furthermore, in isolated artery strips, only fractions C, D and F of DUL8000 
were vasoconstrictory (Figure App X 3). The other fractions did not show 
vasoconstrictory effect. None of the fractions showed vasorelaxatory effect in 
potassium chloride-preconstricted strips. From these results, the cardiovascular 
active fractions of DUL8000 were fractions C and F. The vasoconstrictory 
substance in fraction D was probably carried over from fraction C. 
In summary, DUL8000 contained at least two different cardiovascular active 
substances. Both were hypotensive and vasoconstrictory. These substances found 
in fractions C and F were of different molecular weights. It was difficult to 
reconcile these 2 responses in the rat! 
In order to identify the hypotensive active compounds in fractions C and F of 
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Figure App X 2. Hypotensive effects of different fractions of DUL8000 from 
A to H in male SD rats. The amount (A to G and void) 
administered was 20 mg/kg for each fraction respectively. 
Vertical bars indicate SEM (n=6). 
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C D F 
Figure App X 3. Contractile effect of isolated male SD tail artery strips of 
different fractions of DUL8000 at 300 mg/L. The tension 
preconstricted by KCl on helical strips was 0.78土0.08 g. 
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